Author Index Volume 54 (2016)
The issue number is given in front of the pagination
Aarsland, D., see Bonanni, L. (4) 1649–1657
Aarsland, D., see van Steenoven, I. (1) 287–295
Abadie, C., see Gourmaud, S. (4) 1659–1670
Abbate, C., see Arosio, B. (2) 417–425
Abrahams, J.P., see Tiiman, A. (3) 971–982
Acharya, N.K., see Goldwaser, E.L. (2) 445–456
Acuña-Ayala, H., see Calderón-Garcidueñas, L. (2) 597–613
Adam, K., see Tsolaki, M. (1) 129–133
Adeli, A., see Scharre, D.W. (3) 995–1004
Adzhubei, A.A., see Morozov, A.V. (2) 763–776
Agrawal, P., see Scharre, D.W. (3) 995–1004
Aiyaz, M., see Hakobyan, S. (2) 707–716
Aldebert, J., see Chapleau, M. (3) 941–955
Allali, G., V. Garibotto and F. Assal, Parkinsonism Differentiates Idiopathic Normal Pressure Hydrocephalus from Its Mimics (1) 123–127
Allen, H.R., see Myers, C.A. (4) 1359–1364
Allison, W.T., see Leighton, P.L.A. (1) 3–29
Almeida, O.F.X., see Li, Y. (1) 135–148
Alva, N., see Ettcheto, M. (1) 233–251
Alvarez, A.R., see Estrada, L.D. (3) 1193–1205
Amadio, M., see Marchesi, N. (2) 535–547
Amaratunga, D., see Wijesinghe, P. (4) 1607–1618
Amaro Jr, E., see Grinberg, L.T. (1) 169–174
Ambrose, C.T., The Role of Capillaries in the Lesser Ailments of Old Age and in Alzheimer’s Disease and Vascular Dementia: The Potential of Pro-Therapeutic Angiogenesis (1) 31–43
Ames, D., see Connors, M.H. (1) 149–155
Amin, N.D., see Binukumar, B.K. (2) 525–533
Andersen, B.G., see Zakarias, J.K. (3) 1183–1192
Andersohn, F., see Brüuggenjürgen, B. (4) 1365–1372
Anderson, W.S., see Lozano, A.M. (2) 777–787
Andrés-Benito, P., see Aso, E. (3) 903–912
Anghinah, R., see Grinberg, L.T. (1) 169–174
Antoine, P., see El Haj, M. (2) 515–523
Anton, M., see Ordoñez-Gutierrez, L. (2) 645–656
Antuono, P.G., see Chen, G. (3) 983–993
Apostolova, I., see Ritter, K. (4) 1319–1331
Arcaro, M., see Cioffi, S.M.G. (2) 717–721
Arnold, S.E., see Roalf, D.R. (1) 325–335
Arora, A.S., see Karch, A. (4) 1385–1393
Arosio, B., M. Casati, C. Gussago, E. Ferri, C. Abbate, V. Scortichini, E. Colombo, P.D. Rossi and D. Mari, Adenosine Type A2A Receptor in Peripheral Cell from Patients with Alzheimer’s Disease, Vascular Dementia, and Idiopathic Normal Pressure Hydrocephalus: A New/Old Potential Target (2) 417–425
Asaad, W.F., see Lozano, A.M. (2) 777–787
Ashford, J.W., see Durazzo, T.C. (1) 99–107
Aso, E., P. Andrés-Benito and I. Ferrer, Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model (3) 903–912
Aso, E., see López-González, I. (2) 471–475
Assal, F., see Allali, G. (1) 123–127
Astakhova, T.M., see Morozov, A.V. (2) 763–776
Asthana, S., see Racine, A.M. (4) 1395–1408
Auckland, L.D., see Parham, C.L. (4) 1629–1647
Audekerke, J.V., see Blockx, I. (2) 723–735
Auladell, C., see Ettcheto, M. (1) 233–251
Avila-Ramírez, J., see Calderón-Garcidueñas, L. (2) 597–613
Azqueta, A., see Bengoetxea, X. (3) 1085–1094
Baéz, S., see Santamaría-García, H. (3) 957–970
Baird, A., see Hakobyan, S. (2) 707–716
Baker, S., J.C. Polanco and J. Götz, Extracellular Vesicles Containing P301L Mutant Tau Accelerate Pathological Tau Phosphorylation and Oligomer Formation but Do Not Seed Mature Neurofibrillary Tangles in ALZ17 Mice (3) 1207–1217
Baltuch, G., see Lozano, A.M. (2) 777–787
Bannach, O., see Hülsemann, M. (1) 79–88
Bar, R., see Boehm-Cagan, A. (3) 1219–1233
Barcikowska, M., see Mandecka, M. (1) 157–168
Barczak, A., see Mandecka, M. (1) 157–168
Bard, F., see Blockx, I. (2) 723–735
Barnes, A., see Westona, P.S.J. (4) 1297–1302
Barocco, F., see Cioffi, S.M.G. (2) 717–721
Barrentine, L.W., see Shankle, W.R. (3) 1073–1084
Bartorelli, L., see Sepe-Monti, M. (3) 1235–1246
Baschieri, F., see Chiasserini, D. (1) 55–67
Bauer, C., see Klafki, H.-W. (2) 691–705
Beas-Zarate, C., see Ettcheto, M. (1) 233–251
Beckelman, B.C., S. Day, X. Zhou, M. Donohue, G.K. Gouras, E. Klann, C.D. Keene and T. Ma, Dysregulation of Elongation Factor 1A Expression is Correlated with Synaptic Plasticity Impairments in Alzheimer’s Disease (2) 669–678
Bell, J.S., see Tan, E.C.K. (4) 1425–1435
Bengoetxea, X., A. López de Cerain, A. Azqueta and M.J. Ramirez, Purported Interactions of Amyloid-b and Glucocorticoids in Cytotoxicity and Genotoxicity: Implications in Alzheimer’s Disease (3) 1085–1094
Benito-Cuesta, I., see Ordoñez-Gutierrez, L. (2) 645–656
Bergquist, J., see Musunuri, S. (4) 1671–1686
Berman, S.E., see Racine, A.M. (4) 1395–1408
Bernasconi, M.P., see Mazzeo, S. (4) 1495–1508
Berti, A., see Luccarini, I. (2) 737–750
Bertoux, M., S. Ramanan, A. Slachevsky, S. Wong, F. Henriquez, G. Musa, C. Delgado, E. Flanagan, M. Bottlaender, M. Sarazin, M. Hornberger and B. Dubois, So Close Yet So Far: Executive Contribution to Memory Processing in Behavioral Variant Frontotemporal Dementia (3) 1005–1014
Bhaskar, M., see Binukumar, B.K. (2) 525–533
Bickel, H., see Heser, K. (1) 185–199
Bickel, H., see Wolfsgruber, S. (3) 1135–1146
Bielicki, J.K., see Boehm-Cagan, A. (3) 1219–1233
Bigio, E.H., see Guo, L. (3) 1157–1167
Bilgel, M., see Racine, A.M. (4) 1395–1408
Binukumar, B.K., S.L. Pelech, C. Sutter, V. Shukla, N.D. Amin, P. Grant, M. Bhaskar, S. Skuntz, J. Steiner and H.C. Pant, Profiling of p5, a 24 Amino Acid Inhibitory Peptide Derived from the CDK5 Activator, p35 CDKR1 Against 70 Protein Kinases (2) 525–533
Biscetti, L., see Chiasserini, D. (1) 55–67
Bittner, D., see Ritter, K. (4) 1319–1331
Bix, G., see Parham, C.L. (4) 1629–1647
Bjerke, M., see Somers, C. (1) 383–395
Blanc, F., see van Steenoven, I. (1) 287–295
Blawath, S., see Middelstädt, J. (1) 253–268
Bleckwenn, M., see Heser, K. (1) 185–199
Blennow, K., see Portelius, E. (4) 1593–1605
Blennow, K., see Racine, A.M. (4) 1395–1408
Blockx, I., S. Einstein, P.-J. Guns, J.V. Audekerke, C. Guglielmetti, W. Zago, D. Roose, M. Verhoye, A. Van der Linden and F. Bard, Monitoring Blood-Brain Barrier Integrity Following Amy-loid- ι ι ι Immunotherapy Using Gadolinium-Enhanced MRI in a PDAPP Mouse Model (2) 723–735
Bodin, M., see Portelius, E. (4) 1593–1605
Boehm-Cagan, A., R. Bar, O. Liraz, J.K. Bielicki, J.O. Johansson and D.M. Michaelson, ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies (3) 1219–1233
Bogucka-Kocka, A., see Ułamek-Kozioł, M. (1) 113–121
Bogucki, J., see Ułamek-Kozioł, M. (1) 113–121
Bomanji, J.B., see Westona, P.S.J. (4) 1297–1302
Bonanni, L., R. Franciotti, F. Nobili, M.G. Kramberger, J.-P. Taylor, S. Garcia-Ptacek, N.W. Falasca, F. Famà, R. Cromarty, M. Onofrj, D. Aarsland and on behalf of the E-DLB study group, EEG Markers of Dementia with Lewy Bodies: A Multicenter Cohort Study (4) 1649–1657
Bonanni, L., see van Steenoven, I. (1) 287–295
Booth, K., see Brody, M. (4) 1509–1519
Bossert, I., see Chincarini, A. (4) 1437–1457
Bottlaender, M., see Bertoux, M. (3) 1005–1014
Boundy, K., see Connors, M.H. (1) 149–155
Bourgade, K., G. Dupuis, E.H. Frost and T. Fülöp Jr., Anti-Viral Properties of Amyloid-b Peptides (3) 859–878
Boutoleau-Bretonnière, C., see Magnin, E. (4) 1459–1471
Brambati, S.M., see Chapleau, M. (3) 941–955
Brashear, H.R., see Brody, M. (4) 1509–1519
Brenner, W., see Ritter, K. (4) 1319–1331
Brettschneider, C., see Heser, K. (1) 185–199
Brettschneider, C., see Wolfsgruber, S. (3) 1135–1146
Brezovakova,V., see Zimova, I. (2) 831–843
Britton, G.B., see Villarreal, A.E. (3) 897–901
Brodaty, H., see Connors, M.H. (1) 149–155
Brodtmann, A., see Malpas, C.B. (1) 223–232
Brody, M., E. Liu, J. Di, M. Lu, R.A. Margolin, J.L. Werth, K. Booth, A. Shadman, H.R. Brashear and G. Novak, A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer’s disease (4) 1509–1519
Broich, K., see Gomm, W. (2) 801–808
Bronskill, S.E., see Jaakkimainen, R.L. (1) 337–349
Brouillette, R.M., see Myers, C.A. (4) 1359–1364
Brown, E.E., Y. Iwata, J.K. Chung, P. Gerretsen and A. Graff-Guerrero, Tau in Late-Life Depression: A Systematic Review and Meta-Analysis (2) 615–633
Brüuggenjürgen, B., F. Andersohn, J. Burkowitz, N. Ezzat, M. Gaudig and S.N. Willich, Cohort Study on Predictors of Need for Nursing Care in Alzheimer’s Disease: An Analysis of Healthcare Data (4) 1365–1372
Brzozowska, J., see Ułamek-Kozioł, M. (1) 113–121
Buchert, R., see Ritter, K. (4) 1319–1331
Budziszewska, M., see Mandecka, M. (1) 157–168
Buhl, P., see Struhal, W. (2) 657–667
Burke, A., see Lozano, A.M. (2) 777–787
Burkowitz, J., see Brüuggenjürgen, B. (4) 1365–1372
Burnysheva, K.M., see Morozov, A.V. (2) 763–776
Butt, D., see Jaakkimainen, R.L. (1) 337–349
Caffarra, P., see Cioffi, S.M.G. (2) 717–721
Cai, R., see Sun, J. (1) 175–184
Calabresi, P., see Chiasserini, D. (1) 55–67
Calderón-Garcidueñas, A., see Calderón-Garcidueñas, L. (2) 597–613
Calderón-Garcidueñas, L., J. Avila-Ramírez, A. Calderón-Garcidueñas, T. González-Heredia, H. Acuña-Ayala, C.-k. Chao, C. Thompson, R. Ruiz-Ramos, V. Cortés-González, L. Martínez-Martínez, M.A. García-Pérez, J. Reis, P.S. Mukherjee, R. Torres-Jardón and I. Lachmann, Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer’s and Parkinson’s Diseases in Young Mexico City Residents (2) 597–613
Calderón-Garcidueñas, L., Smoking and Cerebral Oxidative Stress and Air Pollution: A Dreadful Equation with Particulate Matter Involved and One More Powerful Reason Not to Smoke Anything! (1) 109–112
Callahan, J., see Malpas, C.B. (1) 223–232
Callas, P.W., see Cushman, M. (2) 497–503
Calvó-Perxas, L., see Turró-Garriga, O. (4) 1551–1560
Calvo-Rodríguez, M., M. García-Durillo, C. Villalobos and L. Núñez, Aging Enables Ca2+ Overload and Apoptosis Induced by Amy-loid- ι ι ι Oligomers in Rat Hippocampal Neurons: Neuroprotection by Non-Steroidal Anti-Inflammatory Drugs and R-Flurbiprofen in Aging Neurons (1) 207–221
Cam, M., see Portelius, E. (4) 1593–1605
Camins, A., see Ettcheto, M. (1) 233–251
Canudas, J., see Pérez-Grijalba, V. (2) 751–762
Carbonell, T., see Ettcheto, M. (1) 233–251
Carlsson, C.M., see Racine, A.M. (4) 1395–1408
Carmona, M., see López-González, I. (2) 471–475
Casabona, D., see Pérez-Grijalba, V. (2) 751–762
Casamenti, F., see Luccarini, I. (2) 737–750
Casati, M., see Arosio, B. (2) 417–425
Cavone, L., see Luccarini, I. (2) 737–750
Cecchetti, G., see Mazzeo, S. (4) 1495–1508
Chakravarty, M.M., see Lozano, A.M. (2) 777–787
Chamorro, D., see Estrada, L.D. (3) 1193–1205
Chang, L., see Li, Y. (1) 135–148
Chang, S.-I., see Scharre, D.W. (3) 995–1004
Chang, Y.-T., see Portelius, E. (4) 1593–1605
Chao, C.-k., see Calderón-Garcidueñas, L. (2) 597–613
Chapleau, M., J. Aldebert, M. Montembeault and S.M. Brambati, Atrophy in Alzheimer’s Disease and Semantic Dementia: An ALE Meta-Analysis of Voxel-Based Morphometry Studies (3) 941–955
Chapman, B.P., see Ren, P. (1) 69–78
Chatterjee, P., see Rai, N. (3) 1147–1155
Chen, C.L.-H., see Liu, S. (2) 585–595
Chen, G., H. Shu, G. Chen, B.D. Ward, P.G. Antuono, Z. Zhang, S.-J. Li and Alzheimer’s Disease Neuroimaging Initiative, Staging Alzheimer’s Disease Risk by Sequencing Brain Function and Structure, Cerebrospinal Fluid, and Cognition Biomarkers (3) 983–993
Chen, G., see Chen, G. (3) 983–993
Chen, J.X., see Yu, Q. (2) 679–690
Chen, K., see Wang, P. (1) 359–371
Chen, X., see Zhang, H. (3) 1095–1112
Chen, Y., see Yu, L. (1) 297–306
Cheng, B., see Li, D. (1) 89–98
Cheung, C.Y., see Liu, S. (2) 585–595
Chiasserini, D., L. Biscetti, L. Farotti, P. Eusebi, N. Salvadori, V. Lisetti,F. Baschieri, E. Chipi, G. Frattini, E. Stoops, H. Vanderstichele, P. Calabresi and L. Parnetti, Performance Evaluation of an Automated ELISA System for Alzheimer’s Disease Detection in Clinical Routine (1) 55–67
Chincarini, A., F. Sensi, L. Rei, I. Bossert, S. Morbelli, U.P. Guerra, G. Frisoni, A. Padovani, F. Nobili and for the Alzheimer’s Disease Neuroimaging Initiative, Standardized Uptake Value Ratio-Independent Evaluation of Brain Amyloidosis (4) 1437–1457
Chipi, E., see Chiasserini, D. (1) 55–67
Cho, H., see Noh, Y. (3) 1015–1026
Cho, S.-J., see Kang, J.M. (3) 879–889
Chodakowska-Z?ebrowska, M., see Mandecka, M. (1) 157–168
Choe, Y.S., see Noh, Y. (3) 1015–1026
Choo, I.H., see Seo, E.H. (2) 559–568
Choo, I.H., see Seo, E.H. (3) 933–940
Chou, M.-C., see Ho, B.-L. (1) 351–357
Christian, B.T., see Racine, A.M. (4) 1395–1408
Chu, W.C.W., see Lou, W. (1) 397–409
Chung, J.K., see Brown, E.E. (2) 615–633
Cioffi, S.M.G., D. Galimberti, F. Barocco, M. Spallazzi, C. Fenoglio, M. Serpente, M. Arcaro, S. Gardini, E. Scarpini and P. Caffarra, Non Fluent Variant of Primary Progressive Aphasia Due to the Novel GRN g.9543delA(IVS3-2delA) Mutation (2) 717–721
Clark, L.R., see Mueller, K.D. (4) 1539–1550
Clark, L.R., see Racine, A.M. (4) 1395–1408
Clarnette, R., see Connors, M.H. (1) 149–155
Collins, S., see Malpas, C.B. (1) 223–232
Colombo, E., see Arosio, B. (2) 417–425
Colombrita, C., see Marchesi, N. (2) 535–547
Comi, G., see Mazzeo, S. (4) 1495–1508
Conde-Sala, J.-L., see Turró-Garriga, O. (4) 1551–1560
Connors, M.H., D. Ames, K. Boundy, R. Clarnette, S. Kurrle, A. Mander, J. Ward, M. Woodward and H. Brodaty, Mortality in Mild Cognitive Impairment: A Longitudinal Study in Memory Clinics (1) 149–155
Corcoran, N.M., see Malpas, C.B. (1) 223–232
Correani, V., see Martire, S. (1) 307–324
Cortés-González, V., see Calderón-Garcidueñas, L. (2) 597–613
Covaci, A., see Portelius, E. (4) 1593–1605
Cras, P., see Somers, C. (1) 383–395
Crocco, E., see Curiel, R.E. (2) 793–799
Cromarty, R., see Bonanni, L. (4) 1649–1657
Cubinkova, V., see Zimova, I. (2) 831–843
Curiel, R.E., E. Crocco, M. Rosado, R. Duara, M.T. Greig, A. Raffo and D.A. Loewenstein, A Brief Computerized Paired Associate Test for the Detection of Mild Cognitive Impairment in Community-Dwelling Older Adults (2) 793–799
Curole, M.V., see Shankle, W.R. (3) 1073–1084
Cushman, M., P.W. Callas, L.A. McClure, F.W. Unverzagt, V.J. Howard, S.R. Gillett, E.L. Thacker and V.G. Wadley, N-Terminal Pro-B-Type Natriuretic Peptide and Risk of Future Cognitive Impairment in the RE-GARDS Cohort (2) 497–503
Czuczwar, S.J., see Ułamek-Kozioł, M. (1) 113–121
D’Antonio, F., see Trebbastoni, A. (3) 1039–1045
d’Erme, M., see Martire, S. (1) 307–324
da Graça M. Martin, M., see Grinberg, L.T. (1) 169–174
Das, S., see Gertje, E.C. (3) 1027–1037
Davies, P., see Mead, E. (4) 1521–1538
Davis, A.B., see Myers, C.A. (4) 1359–1364
Day, S., see Beckelman, B.C. (2) 669–678
De Beaumont, L., S. Pelleieux, L. Lamarre-Théroux, D. Dea, J. Poirier and the Alzheimer’s Disease Cooperative Study, Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer’s Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects (3) 913–922
De Deyn, P., see Portelius, E. (4) 1593–1605
De Deyn, P.-P., see Somers, C. (1) 383–395
de la Sayette, V., see Magnin, E. (4) 1459–1471
de Lena, C., see Trebbastoni, A. (3) 1039–1045
De Roeck, E., see Somers, C. (1) 383–395
De Roeck, N., see Somers, C. (1) 383–395
De Silva, K.R.D., see Wijesinghe, P. (4) 1607–1618
De Vil, B., see Somers, C. (1) 383–395
Dea, D., see De Beaumont, L. (3) 913–922
Death Preparation and Boredom Reduction as Functions of Reminiscence in Alzheimer’s Disease (2) 515–523
Delgado, C., see Bertoux, M. (3) 1005–1014
Demattei, C., see Renard, D. (4) 1291–1295
Démonet, J.-F., see Magnin, E. (4) 1459–1471
Desai, G.R., see Rai, N. (3) 1147–1155
Desmond, P., see Malpas, C.B. (1) 223–232
Dey, A.B., see Rai, N. (3) 1147–1155
Dey, S., see Rai, N. (3) 1147–1155
Di, J., see Brody, M. (4) 1509–1519
Di Lazzaro, V., see Tombini, M. (4) 1619–1627
Dickensheets, T., see Johnson, L.A. (1) 201–206
Dickeson, S.K., see Parham, C.L. (4) 1629–1647
Dickson, J., see Westona, P.S.J. (4) 1297–1302
Doblhammer, G., see Gomm, W. (2) 801–808
Dobson, R., see Hakobyan, S. (2) 707–716
Doi, T., see Makizako, H. (4) 1473–1482
Donohue, M., see Beckelman, B.C. (2) 669–678
Dovas, K., see Tsolaki, M. (1) 129–133
Dovidchenko, N.V., see Selivanova, O.M. (2) 821–830
Drake, K.E., see Lozano, A.M. (2) 777–787
Duara, R., see Curiel, R.E. (2) 793–799
Dubner, L., see Varghese, M. (2) 477–496
Dubois, B., see Bertoux, M. (3) 1005–1014
Dulcey, A.E., see Estrada, L.D. (3) 1193–1205
Dumurgier, J., see Magnin, E. (4) 1459–1471
Dupuis, G., see Bourgade, K. (3) 859–878
Durazzo, T.C., M. Korecka, J.Q. Trojanowski, M.W. Weiner, R. O’ Hara, J.W. Ashford, L.M. Shaw and for the Alzheimer’s Disease Neuroimaging Initiative, Active Cigarette Smoking in Cognitively-Normal Elders and Probable Alzheimer’s Disease is Associated with Elevated Cerebrospinal Fluid Oxidative Stress Biomarkers (1) 99–107
Durieu, E., see Portelius, E. (4) 1593–1605
Duron, E., see Magnin, E. (4) 1459–1471
Dwivedi, S., see Rai, N. (3) 1147–1155
Dzhus, U.F., see Selivanova, O.M. (2) 821–830
Edwards, M., see Johnson, L.A. (1) 201–206
Edwards, M., see Villarreal, A.E. (3) 897–901
Einstein, S., see Blockx, I. (2) 723–735
El Haj, M. and P. Antoine
El Khoury, J., see Guo, L. (3) 1157–1167
Enderle, A., see Magnin, E. (4) 1459–1471
Engelborghs, S., see Somers, C. (1) 383–395
Erlandsson, A., see Musunuri, S. (4) 1671–1686
Ernst, A., see Wolfsgruber, S. (3) 1135–1146
Erokhov, P.A., see Morozov, A.V. (2) 763–776
Eslambolchilar, P., see Jenkins, A. (3) 1169–1182
Estrada, L.D., D. Chamorro, M.J. Yañez, M. Gonzalez, N. Leal, R. von Bernhardi, A.E. Dulcey, J. Marugan, M. Ferrer, C. Soto, S. Zanlungo, N.C. Inestrosa and A.R. Alvarez, Reduction of Blood Amyloid-b Oligomers in Alzheimer’s Disease Transgenic Mice by c-Abl Kinase Inhibition (3) 1193–1205
Estrella, M., see Ritter, K. (4) 1319–1331
Ettcheto, M., D. Petrov, I. Pedrós, N. Alva, T. Carbonell, C. Beas-Zarate, M. Pallas, C. Auladell, J. Folch and A. Camins, Evaluation of Neuropathological Effects of a High-Fat Diet in a Presymptomatic Alz-heimer’s Disease Stage in APP/PS1 Mice (1) 233–251
Eusebi, P., see Chiasserini, D. (1) 55–67
Evain, S., see Magnin, E. (4) 1459–1471
Eversden, S., see Mead, E. (4) 1521–1538
Evgen’ev, M.B., see Morozov, A.V. (2) 763–776
Exley, C., see Mirzaa, A. (4) 1333–1338
Ezzat, N., see Brüuggenjürgen, B. (4) 1365–1372
Falasca, N.W., see Bonanni, L. (4) 1649–1657
Falautano, M., see Mazzeo, S. (4) 1495–1508
Famà, F., see Bonanni, L. (4) 1649–1657
Fandos, N., see Pérez-Grijalba, V. (2) 751–762
Fang, D., see Yu, Q. (2) 679–690
Fang, Y., see Li, Y. (1) 135–148
Farotti, L., see Chiasserini, D. (1) 55–67
Farr, S.A., K.E. Sandoval, M.L. Niehoff, K.A. Witt, V.B. Kumar and J.E. Morley, Peripheral Administration of GSK-3b Antisense Oligonucleotide Improves Learning and Memory in SAMP8 and Tg2576 Mouse Models of Alzheimer’s Disease (4) 1339–1348
Fenoglio, C., see Cioffi, S.M.G. (2) 717–721
Fernandez, L., see López-González, I. (2) 471–475
Fernandez-Perez, I., see Ordoñez-Gutierrez, L. (2) 645–656
Ferrer, I., see Aso, E. (3) 903–912
Ferrer, I., see López-González, I. (2) 471–475
Ferrer, M., see Estrada, L.D. (3) 1193–1205
Ferri, E., see Arosio, B. (2) 417–425
Fiebach, J.B., see Ritter, K. (4) 1319–1331
Filho, W.J., see Grinberg, L.T. (1) 169–174
Filipcik, P., see Zimova, I. (2) 831–843
Filipek-Gliszczyńska, A., see Mandecka, M. (1) 157–168
Fink, A., see Gomm, W. (2) 801–808
Fiorino, A., see Mazzeo, S. (4) 1495–1508
Fladby, T., see van Steenoven, I. (1) 287–295
Flajolet, M., see Portelius, E. (4) 1593–1605
Flanagan, E., see Bertoux, M. (3) 1005–1014
Foil, H., see Myers, C.A. (4) 1359–1364
Folch, J., see Ettcheto, M. (1) 233–251
Folkerts, A.-K., see Middelstädt, J. (1) 253–268
Fontaine, G., see Portelius, E. (4) 1593–1605
Fontana, M., see Martire, S. (1) 307–324
Foote, K.D., see Lozano, A.M. (2) 777–787
Forte, E., see Martire, S. (1) 307–324
Fosdick, L., see Lozano, A.M. (2) 777–787
Fox, N.C., see Westona, P.S.J. (4) 1297–1302
Foxe, D., see Midorikawa, A. (2) 549–558
Franciotti, R., see Bonanni, L. (4) 1649–1657
Frattini, G., see Chiasserini, D. (1) 55–67
Fried, I., Brain Stimulation in Alzheimer’s Disease (2) 789–791
Frisoni, G., see Chincarini, A. (4) 1437–1457
Fritz, N., see Scharre, D.W. (3) 995–1004
Frost, E.H., see Bourgade, K. (3) 859–878
Fu, Y.H., J.-H.T. Hsiao, G. Paxinos, G.M. Halliday and W.S. Kim, ABCA7 Mediates Phagocytic Clearance of Amy-loid- ι ι ι in the Brain (2)
569–584
Fuchs, A., see Heser, K. (1) 185–199
Fuchs, A., see Wolfsgruber, S. (3) 1135–1146
Fülöp Jr., T., see Bourgade, K. (3) 859–878
Funahashi, Y., see Yoshino, Y. (4) 1349–1357
Furmaga-Jabłońska, W., see Ułamek-Kozioł, M. (1) 113–121
Fuso, A., see Martire, S. (1) 307–324
Gabelle, A., see Magnin, E. (4) 1459–1471
Gabelle, A., see Renard, D. (4) 1291–1295
Gable, S., see Levy, B. (4) 1259–1272
Gabryelewicz, T., see Mandecka, M. (1) 157–168
Gago, M., see Lima, S. (3) 1113–1121
Galimberti, D., see Cioffi, S.M.G. (2) 717–721
Galons, H., see Portelius, E. (4) 1593–1605
Galzitskaya, O.V., see Selivanova, O.M. (2) 821–830
Gamboa, A., see Johnson, L.A. (1) 201–206
Gao, X., see Li, Y. (1) 135–148
Garbis, S.D., see Portelius, E. (4) 1593–1605
García, A., see Santamaría-García, H. (3) 957–970
García-Durillo, M., see Calvo-Rodríguez, M. (1) 207–221
García-Pérez, M.A., see Calderón-Garcidueñas, L. (2) 597–613
Garcia-Ptacek, S., see Bonanni, L. (4) 1649–1657
Gardini, S., see Cioffi, S.M.G. (2) 717–721
Garibotto, V., see Allali, G. (1) 123–127
Garre-Olmo, J., see Turró-Garriga, O. (4) 1551–1560
Garrett, C., see Lima, S. (3) 1113–1121
Gascón-Bayarri, J., see Turró-Garriga, O. (4) 1551–1560
Gasse, C., see Stevnsborg, L. (2) 505–514
Gasse, C., see Zakarias, J.K. (3) 1183–1192
Gaudig, M., see Brüuggenjürgen, B. (4) 1365–1372
Genc, S., see Malpas, C.B. (1) 223–232
Georgiadis, K., see Tsolaki, M. (1) 129–133
Gerretsen, P., see Brown, E.E. (2) 615–633
Gertje, E.C., J. Pluta, S. Das, L. Mancuso, D. Kliot, P. Yushkevich and D. Wolk, Clinical Application of Automatic Segmentation of Medial Temporal Lobe Subregions in Prodromal and Dementia-Level Alzheimer’s Disease (3) 1027–1037
Geula, C., see Guo, L. (3) 1157–1167
Giacobbe, P., see Lozano, A.M. (2) 777–787
Giannakopoulos, P., see Zhang, H. (3) 1095–1112
Gibson, Y., see Mead, E. (4) 1521–1538
Gil-Kulik, P., see Ułamek-Kozioł, M. (1) 113–121
Gill, D.P., see Heath, M. (3) 923–931
Gillett, S.R., see Cushman, M. (2) 497–503
Giubilei, F., see Sepe-Monti, M. (3) 1235–1246
Glyakina, A.V., see Selivanova, O.M. (2) 821–830
Godsey, G., see Goldwaser, E.L. (2) 445–456
Goldwaser, E.L., N.K. Acharya, A. Sarkar, G. Godsey and R.G. Nagele, Breakdown of the Cerebrovasculature and Blood-Brain Barrier: A Mechanistic Link Between Diabetes Mellitus and Alzheimer’s Disease (2) 445–456
Gomm, W., K. von Holt, F. Thomé, K. Broich, W. Maier, K. Weckbecker, A. Fink, G. Doblhammer and B. Haenisch, Regular Benzodiazepine and Z-Substance Use and Risk of Dementia: An Analysis of German Claims Data (2) 801–808
Gonzalez, M., see Estrada, L.D. (3) 1193–1205
González-Heredia, T., see Calderón-Garcidueñas, L. (2) 597–613
Goodson, R., see Mead, E. (4) 1521–1538
Goossens, J., see Somers, C. (1) 383–395
Gorrie, C., see Wijesinghe, P. (4) 1607–1618
Götz, J., see Baker, S. (3) 1207–1217
Gouras, G.K., see Beckelman, B.C. (2) 669–678
Gourmaud, S., F. Mouton-Liger, C. Abadie, E.F. Meurs, C. Paquet and J. Hugon, Dual Kinase Inhibition Affords Extended in vitro Neuroprotection in Amyloid-b Toxicity (4) 1659–1670
Gövercin, M., see Ritter, K. (4) 1319–1331
Govoni, S., see Marchesi, N. (2) 535–547
Graff-Guerrero, A., see Brown, E.E. (2) 615–633
Grajales, S., see Villarreal, A.E. (3) 897–901
Grant, P., see Binukumar, B.K. (2) 525–533
Gräslund, A., see Tiiman, A. (3) 971–982
Green, D., see Jaakkimainen, R.L. (1) 337–349
Greenway, F.L., see Myers, C.A. (4) 1359–1364
Gregory, M.A., see Heath, M. (3) 923–931
Greig, M.T., see Curiel, R.E. (2) 793–799
Grigorashvili, E.I., see Selivanova, O.M. (2) 821–830
Grinberg, L.T., R. Anghinah, C.F. Nascimento, E. Amaro Jr, R.P. Leite, M. da Graça M. Martin, M.S. Naslavsky, L.T. Takada, W.J. Filho, C.A. Pasqualucci and R. Nitrini, Chronic Traumatic Encephalopathy Presenting as Alzheimer’s Disease in a Retired Soccer Player (1) 169–174
Griswold-Prenner, I., see Parham, C.L. (4) 1629–1647
Guerra, U.P., see Chincarini, A. (4) 1437–1457
Guglielmetti, C., see Blockx, I. (2) 723–735
Guns, P.-J., see Blockx, I. (2) 723–735
Guo, L., A. Rezvanian, L. Kukreja, R. Hoveydai, E.H. Bigio, M.-M. Mesulam, J. El Khoury and C. Geula, Postmortem Adult Human Microglia Proliferate in Culture to High Passage and Maintain Their Response to Amyloid-b (3) 1157–1167
Guo, X., see Wang, P. (1) 359–371
Gussago, C., see Arosio, B. (2) 417–425
Haenisch, B., see Gomm, W. (2) 801–808
Hafermann, H., see Klafki, H.-W. (2) 691–705
Häggmark-Månberg, A., see Musunuri, S. (4) 1671–1686
Hakobyan, S., K. Harding, M. Aiyaz, A. Hye, R. Dobson, A. Baird, B. Liu, C.L. Harris, S. Lovestone and B.P. Morgan, Complement Biomarkers as Predictors of Disease Progression in Alzheimer’s Disease (2) 707–716
Hall, J., see Johnson, L.A. (1) 201–206
Haller, S., see Zhang, H. (3) 1095–1112
Halliday, G.M., see Fu, Y.H. (2) 569–584
Hamilton, L., see Mead, E. (4) 1521–1538
Hampel, H., see Ritter, K. (4) 1319–1331
Hannequin, D., see Magnin, E. (4) 1459–1471
Hara, H., F. Ono, S. Nakamura, S. Matsumoto, H. Jin, N. Hattori and T. Tabira, An Oral Ab Vaccine Using a Recombinant Adeno-Associated Virus Vector in Aged Monkeys: Reduction in Plaque Amyloid and Increase in Ab Oligomers (3) 1047–1059
Hara, J., see Shankle, W.R. (3) 1073–1084
Harding, K., see Hakobyan, S. (2) 707–716
Harris, C.L., see Hakobyan, S. (2) 707–716
Hata, S., see Portelius, E. (4) 1593–1605
Hattori, N., see Hara, H. (3) 1047–1059
Haussmann, U., see Klafki, H.-W. (2) 691–705
Haynes, J.-D., see Ritter, K. (4) 1319–1331
Heath, M., J. Weiler, M.A. Gregory, D.P. Gill and R.J. Petrella, A Six-Month Cognitive-Motor and Aerobic Exercise Program Improves Executive Function in Persons with an Objective Cognitive Impairment: A Pilot Investigation Using the Antisaccade Task (3) 923–931
Heikkilä, K., see Iso-Markku, P. (4) 1303–1317
Hemachandra Reddy, P., see Vijayan, M. (2) 427–443
Henriquez, F., see Bertoux, M. (3) 1005–1014
Hermann, B., see Mueller, K.D. (4) 1539–1550
Herrera, J.L., see Ordoñez-Gutierrez, L. (2) 645–656
Herrmann, N., see Jaakkimainen, R.L. (1) 337–349
Herrmann, N., see Rosenberg, P.B. (1) 373–381
Herrmann, Y., see Hülsemann, M. (1) 79–88
Heser, K., M. Bleckwenn, B. Wiese, S. Mamone, S.G. Riedel-Heller, J. Stein, D. Lühmann, T. Posselt, A. Fuchs, M. Pentzek, S. Weyerer, J. Werle, D. Weeg, H. Bickel, C. Brettschneider, H.-H. König, W. Maier, M. Scherer and M. Wagner for the AgeCoDe Study Group, Late-Life Depressive Symptoms and Lifetime History of Major Depression: Cognitive Deficits are Largely Due to Incipient Dementia rather than Depression (1) 185–199
Hicks, R.J., see Malpas, C.B. (1) 223–232
Hilal, S., see Liu, S. (2) 585–595
Hirtz, C., see Renard, D. (4) 1291–1295
Ho, B.-L., Y.-H. Kao, M.-C. Chou and Y.-H. Yang, Cerebral White Matter Changes on Therapeutic Response to Rivastigmine in Alzheimer’s Disease (1) 351–357
Ho, L., see Varghese, M. (2) 477–496
Hodges, J.R., see Midorikawa, A. (2) 549–558
Honda, K., Cerebral Arterial Occlusion Did Not Promote the Prevalence of Cerebral Amyloid Angiopathy (1) 269–274
Hong, X., see Wang, H. (1) 275–286
Hong, Y., see Yu, L. (1) 297–306
Hornberger, M., see Bertoux, M. (3) 1005–1014
Hotta, R., see Makizako, H. (4) 1473–1482
Hovens, C.M., see Malpas, C.B. (1) 223–232
Hoveydai, R., see Guo, L. (3) 1157–1167
Howard, V.J., see Cushman, M. (2) 497–503
Hromadka, T., see Zimova, I. (2) 831–843
Hsiao, J.-H.T., see Fu, Y.H. (2) 569–584
Hu, B., see Wang, P. (1) 359–371
Huang, P., see Qiu, T. (4) 1483–1493
Huang, R., see Sun, J. (1) 175–184
Huang, Y., see Li, D. (1) 89–98
Huemer, M., see Struhal, W. (2) 657–667
Hugon, J., see Gourmaud, S. (4) 1659–1670
Hugon, J., see Magnin, E. (4) 1459–1471
Hulathduwa, S., see Wijesinghe, P. (4) 1607–1618
Hülsemann, M., C. Zafiu, K. Kühbach, N. Lühmann, Y. Herrmann, L. Peters, C. Linnartz, J. Willbold, K. Kravchenko, A. Kulawik, S. Willbold, O. Bannach and D. Willbold, Biofunctionalized Silica Nanoparticles: Standards in Amy-loid- ι ι ι Oligomer-Based Diagnosis of Alzheimer’s Disease (1) 79–88
Hutton, M., see Mead, E. (4) 1521–1538
Hye, A., see Hakobyan, S. (2) 707–716
Ibañez, A., see Santamaría-García, H. (3) 957–970
Iga, J.-i., see Yoshino, Y. (4) 1349–1357
Inestrosa, N.C., see Estrada, L.D. (3) 1193–1205
Ingelsson, M., see Musunuri, S. (4) 1671–1686
Inghilleri, M., see Trebbastoni, A. (3) 1039–1045
Insardá, P., see Tombini, M. (4) 1619–1627
Insua, D., see Pérez-Grijalba, V. (2) 751–762
Iso-Markku, P., K. Waller, E. Vuoksimaa, K. Heikkilä, J. Rinne, J. Kaprio and U.M. Kujala, Midlife Physical Activity and Cognition Later in Life: A Prospective Twin Study (4) 1303–1317
Itzhaki, R.F., Herpes and Alzheimer’s Disease: Subversion in the Central Nervous System and How It Might Be Halted (4) 1273–1281
Ivanov, A.S., see Khmeleva, S.A. (2) 809–819
Ivers, N., see Jaakkimainen, R.L. (1) 337–349
Iwata, N., see Matsunaga, S. (2) 635–643
Iwata, Y., see Brown, E.E. (2) 615–633
Jaakkimainen, R.L., S.E. Bronskill, M.C. Tierney, N. Herrmann, D. Green, J. Young, N. Ivers, D. Butt, J. Widdifield and K. Tu, Identification of Physician-Diagnosed Alzheimer’s Disease and Related Dementias in Population-Based Administrative Data: A Validation Study Using Family Physicians’ Electronic Medical Records (1) 337–349
Jabłoński, M., see Ułamek-Kozioł, M. (1) 113–121
Jadhav, S., see Zimova, I. (2) 831–843
Jager, A., see Magnin, E. (4) 1459–1471
Jakobsen, S., see Zakarias, J.K. (3) 1183–1192
Januszewski, S., see Ułamek-Kozioł, M. (1) 113–121
Jarvet, J., see Tiiman, A. (3) 971–982
Jedynak, B., see Racine, A.M. (4) 1395–1408
Jenkins, A., S. Lindsay, P. Eslambolchilar, I.M. Thornton and A. Tales, Administering Cognitive Tests Through Touch Screen Tablet Devices: Potential Issues (3) 1169–1182
Jensen-Dahm, C., see Stevnsborg, L. (2) 505–514
Jensen-Dahm, C., see Zakarias, J.K. (3) 1183–1192
Jeon, S., see Noh, Y. (3) 1015–1026
Jessen, F., see Wolfsgruber, S. (3) 1135–1146
Jin, H., see Hara, H. (3) 1047–1059
Johansson, J.O., see Boehm-Cagan, A. (3) 1219–1233
John, B., see Trebbastoni, A. (3) 1039–1045
Johnson, L.A., A. Gamboa, R. Vintimilla, M. Edwards, J. Hall, B. Weiser, M. Yadav, T. Dickensheets and S.E. O’Bryant, A Depressive Endophenotype for Predicting Cognitive Decline among Mexican American Adults and Elders (1) 201–206
Johnson, S.C., see Mueller, K.D. (4) 1539–1550
Johnson, S.C., see Racine, A.M. (4) 1395–1408
Johnson, W.D., see Myers, C.A. (4) 1359–1364
Jones, S., see Mead, E. (4) 1521–1538
Kalbe, E., see Middelstädt, J. (1) 253–268
Kang, J.M., B.K. Yeon, S.-J. Cho and Y.-H. Suh, Stem Cell Therapy for Alzheimer’s Disease: A Review of Recent Clinical Trials (3) 879–889
Kang, S.-H., see Seo, E.H. (2) 559–568
Kao, Y.-H., see Ho, B.-L. (1) 351–357
Kaprio, J., see Iso-Markku, P. (4) 1303–1317
Karakostas, A., see Lazarou, I. (4) 1561–1591
Karakostas, A., see Tsolaki, M. (1) 129–133
Karathanasi, E., see Tsolaki, M. (1) 129–133
Karch, A., F. Llorens, M. Schmitz, A.S. Arora, S. Zafar, P. Lange, C. Schmidt and I. Zerr, Stratification by Genetic and Demographic Characteristics Improves Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers in Rapidly Progressive Dementia (4) 1385–1393
Karg, F., see Portelius, E. (4) 1593–1605
Karlström, A.E., see Tiiman, A. (3) 971–982
Karpov, V.L., see Morozov, A.V. (2) 763–776
Kataki, M., see Scharre, D.W. (3) 995–1004
Kayani, I., see Westona, P.S.J. (4) 1297–1302
Keene, C.D., see Beckelman, B.C. (2) 669–678
Kegelmeyer, D., see Scharre, D.W. (3) 995–1004
Keller, J.N., see Myers, C.A. (4) 1359–1364
Kestoras, D., see Mead, E. (4) 1521–1538
Khaiboullina, S.F., see Mukhamedyarov, M.A. (4) 1373–1383
Khmeleva, S.A., S.P. Radko, S.A. Kozin, Y.Y. Kiseleva, Y.V. Mezentsev, V.A. Mitkevich, L.K. Kurbatov, A.S. Ivanov and A.A. Makarov, Zinc-Mediated Binding of Nucleic Acids to Amy-loid- ι ι ι Aggregates: Role of Histidine Residues (2) 809–819
Khoonsari, P.E., see Musunuri, S. (4) 1671–1686
Kim, G.H., see Noh, Y. (3) 1015–1026
Kim, H., see Seo, E.H. (3) 933–940
Kim, H.J., see Noh, Y. (3) 1015–1026
Kim, J.-H., see Noh, Y. (3) 1015–1026
Kim, J.S., see Noh, Y. (3) 1015–1026
Kim, M., see Zhang, H. (3) 1095–1112
Kim, S.H., see Seo, E.H. (2) 559–568
Kim, W.S., see Fu, Y.H. (2) 569–584
Kindy, M.S., see Taheri, S. (3) 1061–1072
King, A., see Mirzaa, A. (4) 1333–1338
Kiseleva, Y.Y., see Khmeleva, S.A. (2) 809–819
Kishi, T., see Matsunaga, S. (2) 635–643
Kiyasov, A.P., see Mukhamedyarov, M.A. (4) 1373–1383
Klafki, H.-W., H. Hafermann, C. Bauer, U. Haussmann, I. Kraus, J. Schuchhardt, S. Muck, N. Scherbaum and J. Wiltfang, Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amy-loid- ι ι ι Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort (2) 691–705
Klann, E., see Beckelman, B.C. (2) 669–678
Kleineidam, L., see Wolfsgruber, S. (3) 1135–1146
Klimova, B., see Maresova, P. (3) 1123–1133
Kliot, D., see Gertje, E.C. (3) 1027–1037
Kloos, A., see Scharre, D.W. (3) 995–1004
Koch, P., see Portelius, E. (4) 1593–1605
Kocki, J., see Ułamek-Kozioł, M. (1) 113–121
Kompatsiaris, I., see Lazarou, I. (4) 1561–1591
Kompatsiaris, I., see Tsolaki, M. (1) 129–133
König, H.-H., see Heser, K. (1) 185–199
König, H.-H., see Wolfsgruber, S. (3) 1135–1146
Korecka, M., see Durazzo, T.C. (1) 99–107
Koscik, R.L., see Mueller, K.D. (4) 1539–1550
Koscik, R.L., see Racine, A.M. (4) 1395–1408
Kostyk, S.K., see Scharre, D.W. (3) 995–1004
Kozin, S.A., see Khmeleva, S.A. (2) 809–819
Kramberger, M.G., see Bonanni, L. (4) 1649–1657
Kramberger, M.G., see van Steenoven, I. (1) 287–295
Kraus, I., see Klafki, H.-W. (2) 691–705
Kravchenko, K., see Hülsemann, M. (1) 79–88
Ksie?z?ak-Reding, H., see Varghese, M. (2) 477–496
Kuca, K., see Maresova, P. (3) 1123–1133
Kühbach, K., see Hülsemann, M. (1) 79–88
Kujala, U.M., see Iso-Markku, P. (4) 1303–1317
Kukreja, L., see Guo, L. (3) 1157–1167
Kulawik, A., see Hülsemann, M. (1) 79–88
Kulikova, A.A., see Morozov, A.V. (2) 763–776
Kultima, K., see Musunuri, S. (4) 1671–1686
Kumar, R., see Rai, N. (3) 1147–1155
Kumar, V.B., see Farr, S.A. (4) 1339–1348
Kumara, K.S., see Wijesinghe, P. (4) 1607–1618
Kurbatov, L.K., see Khmeleva, S.A. (2) 809–819
Kurrle, S., see Connors, M.H. (1) 149–155
Kuruppu, S., N.W. Rajapakse, A.J. Spicer, H.C. Parkington and A.I. Smith, Stimulating the Activity of Amyloid-Beta Degrading Enzymes: A Novel Approach for the Therapeutic Manipulation of Amyloid-Beta Levels (3) 891–895
Lachmann, I., see Calderón-Garcidueñas, L. (2) 597–613
Lacosta, A.M., see Pérez-Grijalba, V. (2) 751–762
Lahrmann, H., see Struhal, W. (2) 657–667
Lamarre-Théroux, L., see De Beaumont, L. (3) 913–922
Lanctôt, K.L., see Rosenberg, P.B. (1) 373–381
Landin-Romero, R., see Midorikawa, A. (2) 549–558
Lange, C., see Ritter, K. (4) 1319–1331
Lange, P., see Karch, A. (4) 1385–1393
Lannfelt, L., see Musunuri, S. (4) 1671–1686
Lapucci, A., see Luccarini, I. (2) 737–750
LaRue, A., see Mueller, K.D. (4) 1539–1550
Lazarou, I., A. Karakostas, T.G. Stavropoulos, T. Tsompanidis, G. Meditskos, I. Kompatsiaris and M. Tsolaki, A Novel and Intelligent Home Monitoring System for Care Support of Elders with Cognitive Impairment (4) 1561–1591
Lazarou, I., see Tsolaki, M. (1) 129–133
Leal, N., see Estrada, L.D. (3) 1193–1205
Lee, J.-H., see Noh, Y. (3) 1015–1026
Lee, J.M., see Noh, Y. (3) 1015–1026
Lee, J.Y., see Portelius, E. (4) 1593–1605
Lee, K.-H., see Noh, Y. (3) 1015–1026
Lee, K.H., see Seo, E.H. (3) 933–940
Lehmann, S., see Renard, D. (4) 1291–1295
Leighton, P.L.A., and W.T. Allison, Protein Misfolding in Prion and Prion-Like Diseases: Reconsidering a Required Role for Protein Loss-of-Function (1) 3–29
Leite, R.P., see Grinberg, L.T. (1) 169–174
Lemstra, A.W., see van Steenoven, I. (1) 287–295
Leoutsakos, J.-M., see Lozano, A.M. (2) 777–787
Leuxe, C., see Portelius, E. (4) 1593–1605
Levy, B., E. Tsoy and S. Gable, Developing Cognitive Markers of Alzheimer’s Disease for Primary Care: Implications for Behavioral and Global Prevention (4) 1259–1272
Leyton, C.E., see Midorikawa, A. (2) 549–558
Li, D., Y. Huang, B. Cheng, J. Su, W.-X. Zhou and Y.-X. Zhang, Streptozotocin Induces Mild Cognitive Impairment at Appropriate Doses in Mice as Determined by Long-Term Potentiation and the Morris Water Maze (1) 89–98
Li, G., see Zhang, H. (3) 1095–1112
Li, H., see Li, Y. (1) 135–148
Li, S., see Wang, H. (1) 275–286
Li, S.-J., see Chen, G. (3) 983–993
Li, Y., L. Chang, Y. Song, X. Gao, F. Roselli, J. Liu, W. Zhou, Y. Fang, W. Ling, H. Li, O.F.X. Almeida and Y. Wu, Astrocytic GluN2A and GluN2B Oppose the Synaptotoxic Effects of Amy-loid- ι ι ι 1-40 in Hippocampal Cells (1) 135–148
Liao, W., see Yuan, B. (4) 1409–1423
Lima, L.M., see Mukhamedyarov, M.A. (4) 1373–1383
Lima, S., M. Gago, C. Garrett and M.G. Pereira, Predictors and Moderators of Quality of Life in Alzheimer’s Disease Patients (3) 1113–1121
Lin, F., see Ren, P. (1) 69–78
Linder, S., see Scharre, D.W. (3) 995–1004
Lindgren, J., see Tiiman, A. (3) 971–982
Lindsay, S., see Jenkins, A. (3) 1169–1182
Ling, W., see Li, Y. (1) 135–148
Linnartz, C., see Hülsemann, M. (1) 79–88
Liraz, O., see Boehm-Cagan, A. (3) 1219–1233
Lisetti, V., see Chiasserini, D. (1) 55–67
Liu, B., see Hakobyan, S. (2) 707–716
Liu, D., see Yuan, B. (4) 1409–1423
Liu, E., see Brody, M. (4) 1509–1519
Liu, J., see Li, Y. (1) 135–148
Liu, S., Y.-T. Ong, S. Hilal, Y.M. Loke, T.Y. Wong, C.L.-H. Chen, C.Y. Cheung and J. Zhou, The Association Between Retinal Neuronal Layer and Brain Structure is Disrupted in Patients with Cognitive Impairment and Alzheimer’s Disease (2) 585–595
Llorens, F., see Karch, A. (4) 1385–1393
Lo, R.Y., see Ren, P. (1) 69–78
Loewenstein, D.A., see Curiel, R.E. (2) 793–799
Loke, Y.M., see Liu, S. (2) 585–595
Lombardi, V.C., see Mukhamedyarov, M.A. (4) 1373–1383
Londos, E., see van Steenoven, I. (1) 287–295
López de Cerain, A., see Bengoetxea, X. (3) 1085–1094
López, L., see Villarreal, A.E. (3) 897–901
López-González, I., A. Palmeira, E. Aso, M. Carmona, L. Fernandez and I. Ferrer, FOXP2 Expression in Frontotemporal Lobar Degeneration-Tau (2) 471–475
Lou, W., L. Shi, A. Wong, W.C.W. Chu, V.C.T. Mok and D. Wang, Changes of Cerebral Perfusion and Functional Brain Network Organization in Patients with Mild Cognitive Impairment (1) 397–409
Lovestone, S., see Hakobyan, S. (2) 707–716
Lozano, A.M., L. Fosdick, M.M. Chakravarty,
J.-M. Leoutsakos, C. Munro, E. Oh, K.E. Drake, C.H. Lyman, P.B. Rosenberg, W.S. Anderson, D.F. Tang-Wai, J.C. Pendergrass, S. Salloway, W.F. Asaad, F.A. Ponce, A. Burke, M. Sabbagh, D.A. Wolk, G. Baltuch, M.S. Okun, K.D. Foote, M.P. McAndrews, P. Giacobbe, S.D. Targum, C.G. Lyketsos and G.S. Smith, A Phase II Study of Fornix Deep Brain Stimulation in Mild Alzheimer’s Disease (2) 777–787
Lu, C.Y., see Tan, E.C.K. (4) 1425–1435
Lu, M., see Brody, M. (4) 1509–1519
Luccarini, I., D. Pantano, P. Nardiello, L. Cavone, A. Lapucci, C. Miceli, C. Nediani, A. Berti, M. Stefani and F. Casamenti, The Polyphenol Oleuropein Aglycone Modulates the PARP1-SIRT1 Interplay: An In Vitro and In Vivo Study (2) 737–750
Luck, T., see Wolfsgruber, S. (3) 1135–1146
Lühmann, D., see Heser, K. (1) 185–199
Lühmann, D., see Wolfsgruber, S. (3) 1135–1146
Lühmann, N., see Hülsemann, M. (1) 79–88
Lunn, M.P., see Westona, P.S.J. (4) 1297–1302
Luo, J., see Tiiman, A. (3) 971–982
Luo, X., see Qiu, T. (4) 1483–1493
Luyckx, J., see Somers, C. (1) 383–395
Lyketsos, C.G., see Lozano, A.M. (2) 777–787
Lyman, C.H., see Lozano, A.M. (2) 777–787
Ma, T., see Beckelman, B.C. (2) 669–678
Mabondzo, A., see Portelius, E. (4) 1593–1605
Macfarlane, S., see Malpas, C.B. (1) 223–232
Magnani, G., see Mazzeo, S. (4) 1495–1508
Magnin, E., J.-F. Démonet, D. Wallon, J. Dumurgier, A.-C. Troussière, A. Jager, E. Duron, A. Gabelle, V. de la Sayette, L. Volpe-Gillot, G. Tio, S. Evain, C. Boutoleau-Bretonnière, A. Enderle, F. Mouton-Liger, P. Robert, D. Hannequin, F. Pasquier, J. Hugon, C. Paquet and on behalf of ePLM collaborators, Primary Progressive Aphasia in the Network of French Alzheimer Plan Memory Centers (4) 1459–1471
Mahringer, C., see Struhal, W. (2) 657–667
Maier, W., see Gomm, W. (2) 801–808
Maier, W., see Heser, K. (1) 185–199
Maier, W., see Wolfsgruber, S. (3) 1135–1146
Makarov, A.A., see Khmeleva, S.A. (2) 809–819
Makarov, A.A., see Morozov, A.V. (2) 763–776
Makino, K., see Makizako, H. (4) 1473–1482
Makizako, H., H. Shimada, T. Doi, K. Tsutsumimoto, R. Hotta, S. Nakakubo, K. Makino and T. Suzuki, Comorbid Mild Cognitive Impairment and Depressive Symptoms Predict Future Dementia in Community Older Adults: A 24-Month Follow-Up Longitudinal Study (4) 1473–1482
Malpas, C.B., L. Vivash, S. Genc, M.M. Saling, P. Desmond, C. Steward, R.J. Hicks, J. Callahan, A. Brodtmann, S. Collins, S. Macfarlane, N.M. Corcoran, C.M. Hovens, D. Velakoulis and T.J. O’Brien, A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer’s Disease (1) 223–232
Mamone, S., see Heser, K. (1) 185–199
Mancuso, L., see Gertje, E.C. (3) 1027–1037
Mandecka, M., M. Budziszewska, A. Barczak, B. Pepłońska, M. Chodakowska-Z?ebrowska, A. Fil-ipek-Gliszczyńska, M. Nesteruk, M. Styczyńska, M. Barcikowska and T. Gabryelewicz, Association between Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer’s Disease (1) 157–168
Mander, A., see Connors, M.H. (1) 149–155
Manousopoulou, A., see Portelius, E. (4) 1593–1605
Mapstone, M., see Ren, P. (1) 69–78
Maras, B., see Martire, S. (1) 307–324
Marchenkov, V.V., see Selivanova, O.M. (2) 821–830
Marchesi, N., M. Amadio, C. Colombrita, S. Govoni, A. Ratti and A. Pascale, PKC Activation Counteracts ADAM10 Deficit in HuD-Silenced Neuroblastoma Cells (2) 535–547
Maresova, P., B. Klimova, M. Novotny and K. Kuca, Alzheimer’s and Parkinson’s Diseases: Expected Economic Impact on Europe—A Call for a Uniform European Strategy (3) 1123–1133
Margolin, R.A., see Brody, M. (4) 1509–1519
Mari, D., see Arosio, B. (2) 417–425
Martin, C.K., see Myers, C.A. (4) 1359–1364
Martin, J.-J., see Somers, C. (1) 383–395
Martinez, A., see Santamaría-García, H. (3) 957–970
Martínez-Martínez, L., see Calderón-Garcidueñas, L. (2) 597–613
Martire, S., A. Fuso, L. Mosca, E. Forte, V. Correani, M. Fontana, S. Scarpa, B. Maras and M. d’Erme, Bioenergetic Impairment in Animal and Cellular Models of Alzheimer’s Disease: PARP-1 Inhibition Rescues Metabolic Dysfunctions (1) 307–324
Marugan, J., see Estrada, L.D. (3) 1193–1205
Matallana, D., see Santamaría-García, H. (3) 957–970
Matsumoto, S., see Hara, H. (3) 1047–1059
Matsunaga, S., T. Kishi and N. Iwata, Yokukansan in the Treatment of Behavioral and Psychological Symptoms of Dementia: An Updated Meta-Analysis of Randomized Controlled Trials (2) 635–643
Mäurer, A., see Ritter, K. (4) 1319–1331
Mazzeo, S., R. Santangelo, M.P. Bernasconi, G. Cecchetti, A. Fiorino, P. Pinto, G. Passerini, M. Falautano, G. Comi and G. Magnani, Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer’s Disease Dementia (4) 1495–1508
McAndrews, M.P., see Lozano, A.M. (2) 777–787
McClure, L.A., see Cushman, M. (2) 497–503
McCully, K.S., Homocysteine, Infections, Polyamines, Oxidative Metabolism, and the Pathogenesis of Dementia and Atherosclerosis (4) 1283–1290
McGeer, E.G., see McGeer, P.L. (3) 853–857
McGeer, P.L., J. Rogers and E.G. McGeer, Inflammation, Antiinflammatory Agents, and Alzheimer’s Disease: The Last 22 Years (3) 853–857
Mead, E., D. Kestoras, Y. Gibson, L. Hamilton, R. Goodson, S. Jones, S. Eversden, P. Davies, M. O’Neill, M. Hutton, P. Szekeres and J. Wolak, Halting of Caspase Activity Protects Tau from MC1-Conformational Change and Aggregation (4) 1521–1538
Mechanic-Hamilton, D., see Roalf, D.R. (1) 325–335
Meditskos, G., see Lazarou, I. (4) 1561–1591
Meijer, L., see Portelius, E. (4) 1593–1605
Mende, C., see Ritter, K. (4) 1319–1331
Mesulam, M.-M., see Guo, L. (3) 1157–1167
Meurs, E.F., see Gourmaud, S. (4) 1659–1670
Mezentsev, Y.V., see Khmeleva, S.A. (2) 809–819
Miceli, C., see Luccarini, I. (2) 737–750
Michaelson, D.M., see Boehm-Cagan, A. (3) 1219–1233
Middelstädt, J., A.-K. Folkerts, S. Blawath and E. Kalbe, Cognitive Stimulation for People with Dementia in Long-Term Care Facilities: Baseline Cognitive Level Predicts Cognitive Gains, Moderated by Depression (1) 253–268
Midorikawa, A., C.E. Leyton, D. Foxe, R. Landin-Romero, J.R. Hodges and O. Piguet, All Is Not Lost: Positive Behaviors in Alzheimer’s Disease and Behavioral-Variant Frontotemporal Dementia with Disease Severity (2) 549–558
Mikus, M., see Musunuri, S. (4) 1671–1686
Mintzer, J.E., see Rosenberg, P.B. (1) 373–381
Mirzaa, A., A. King, C. Troakes and C. Exley, The Identification of Aluminum in Human Brain Tissue Using Lumogallion and Fluorescence Microscopy (4) 1333–1338
Mitkevich, V.A., see Khmeleva, S.A. (2) 809–819
Mitkevich, V.A., see Morozov, A.V. (2) 763–776
Moberg, P.J., see Roalf, D.R. (1) 325–335
Mok, V.C.T., see Lou, W. (1) 397–409
Mollenhauer, B., see van Steenoven, I. (1) 287–295
Montalván, A., see Villarreal, A.E. (3) 897–901
Montañés, M., see Pérez-Grijalba, V. (2) 751–762
Montembeault, M., see Chapleau, M. (3) 941–955
Moos, T., see Zakarias, J.K. (3) 1183–1192
Morbelli, S., see Chincarini, A. (4) 1437–1457
Morgan, B.P., see Hakobyan, S. (2) 707–716
Mori, T., see Yoshino, Y. (4) 1349–1357
Morley, J.E., see Farr, S.A. (4) 1339–1348
Morozov, A.V., A.A. Kulikova, T.M. Astakhova, V.A. Mitkevich, K.M. Burnysheva, A.A. Adzhubei, P.A. Erokhov, M.B. Evgen’ev, N.P. Sharova, V.L. Karpov and A.A. Makarov, Amy-loid- ι ι ι Increases Activity of Proteasomes Capped with 19S and 11S Regulators (2) 763–776
Mörtl, C., see Struhal, W. (2) 657–667
Mosca, L., see Martire, S. (1) 307–324
Mösch, E., see Wolfsgruber, S. (3) 1135–1146
Mouton-Liger, F., see Gourmaud, S. (4) 1659–1670
Mouton-Liger, F., see Magnin, E. (4) 1459–1471
Muck, S., see Klafki, H.-W. (2) 691–705
Mueller, K.D., R.L. Koscik, L.S. Turkstra, S.K. Riedeman, A. LaRue, L.R. Clark, B. Hermann, M.A. Sager and S.C. Johnson, Connected Language in Late Middle-Aged Adults at Risk for Alzheimer’s Disease (4) 1539–1550
Mueller, K.D., see Racine, A.M. (4) 1395–1408
Mukhamedyarov, M.A., A.A. Rizvanov, E.Z. Yakupov, A.L. Zefirov, A.P. Kiyasov, H.J. Reis, A.L. Teixeira, L.B. Vieira, L.M. Lima, I.I. Salafutdinov, E.O. Petukhova, S.F. Khaiboullina, K.A. Schlauch, V.C. Lombardi and A. Palotás, Transcriptional Analysis of Blood Lymphocytes and Skin Fibroblasts, Keratinocytes, and Endothelial Cells as a Potential Biomarker for Alzheimer’s Disease (4) 1373–1383
Mukherjee, P.S., see Calderón-Garcidueñas, L. (2) 597–613
Mummery, C.J., see Westona, P.S.J. (4) 1297–1302
Munro, C., see Lozano, A.M. (2) 777–787
Musa, G., see Bertoux, M. (3) 1005–1014
Musunuri, S., P.E. Khoonsari, M. Mikus, M. Wetterhall, A. Häggmark-Månberg, L. Lannfelt, A. Erlandsson, J. Bergquist, M. Ingelsson, G. Shevchenko, P. Nilsson and K. Kultima, Increased Levels of Extracellular Microvesicle Markers and Decreased Levels of Endocytic/Exocytic Proteins in the Alzheimer’s Disease Brain (4) 1671–1686
Myers, C.A., J.N. Keller, H.R. Allen, R.M. Brouillette, H. Foil, A.B. Davis, F.L. Greenway, W.D. Johnson and C.K. Martin, Reliability and Validity of a Novel Internet-Based Battery to Assess Mood and Cognitive Function in the Elderly (4) 1359–1364
Na, D.L., see Noh, Y. (3) 1015–1026
Nagaraja, H.N., see Scharre, D.W. (3) 995–1004
Nagele, R.G., see Goldwaser, E.L. (2) 445–456
Nakakubo, S., see Makizako, H. (4) 1473–1482
Nakamura, S., see Hara, H. (3) 1047–1059
Nardiello, P., see Luccarini, I. (2) 737–750
Nascimento, C.F., see Grinberg, L.T. (1) 169–174
Naslavsky, M.S., see Grinberg, L.T. (1) 169–174
Nediani, C., see Luccarini, I. (2) 737–750
Nesteruk, M., see Mandecka, M. (1) 157–168
Nicholas, C.R., see Racine, A.M. (4) 1395–1408
Niehoff, M.L., see Farr, S.A. (4) 1339–1348
Nielsen, T.R., see Stevnsborg, L. (2) 505–514
Niemantsverdriet, E., see Somers, C. (1) 383–395
Nilsson, P., see Musunuri, S. (4) 1671–1686
Nitrini, R., see Grinberg, L.T. (1) 169–174
Nobili, F., see Bonanni, L. (4) 1649–1657
Nobili, F., see Chincarini, A. (4) 1437–1457
Noh, Y., S.W. Seo, S. Jeon, J.M. Lee, J.S. Kim,
J.-H. Lee, J.-H. Kim, G.H. Kim, B.S. Ye, H. Cho, H.J. Kim, C.W. Yoon, Y.S. Choe, K.-H. Lee, M.W. Weiner and D.L. Na, The Role of Cerebrovascular Disease in Amyloid Deposition (3) 1015–1026
Nørgaard, A., see Zakarias, J.K. (3) 1183–1192
Norton, D., see Racine, A.M. (4) 1395–1408
Novak, G., see Brody, M. (4) 1509–1519
Novak, M., see Zimova, I. (2) 831–843
Novotny, M., see Maresova, P. (3) 1123–1133
Núñez, L., see Calvo-Rodríguez, M. (1) 207–221
O’ Hara, R., see Durazzo, T.C. (1) 99–107
O’Brien, T.J., see Malpas, C.B. (1) 223–232
O’Bryant, S.E., see Johnson, L.A. (1) 201–206
O’Bryant, S.E., see Villarreal, A.E. (3) 897–901
O’Neill, M., see Mead, E. (4) 1521–1538
Oh, E., see Lozano, A.M. (2) 777–787
Okun, M.S., see Lozano, A.M. (2) 777–787
Olsen, I., and S.K. Singhrao, Inflammasome Involvement in Alzheimer’s Disease (1) 45–53
Olsson, L., see Tiiman, A. (3) 971–982
Omori, C., see Portelius, E. (4) 1593–1605
Onesti, E., see Trebbastoni, A. (3) 1039–1045
Ong, Y.-T., see Liu, S. (2) 585–595
Ono, F., see Hara, H. (3) 1047–1059
Onofrj, M., see Bonanni, L. (4) 1649–1657
Ordoñez-Gutierrez, L., I. Fernandez-Perez, J.L. Herrera, M. Anton, I. Benito-Cuesta and F. Wandosell, A ι ι ι PP/PS1 Transgenic Mice Show Sex Differences in the Cerebellum Associated with Aging (2) 645–656
Oumata, N., see Portelius, E. (4) 1593–1605
Ozaki, Y., see Yoshino, Y. (4) 1349–1357
Padovani, A., see Chincarini, A. (4) 1437–1457
Pallas, M., see Ettcheto, M. (1) 233–251
Palmeira, A., see López-González, I. (2) 471–475
Palotás, A., see Mukhamedyarov, M.A. (4) 1373–1383
Pannee, J., see Portelius, E. (4) 1593–1605
Pant, H.C., see Binukumar, B.K. (2) 525–533
Pantano, D., see Luccarini, I. (2) 737–750
Paquet, C., see Gourmaud, S. (4) 1659–1670
Paquet, C., see Magnin, E. (4) 1459–1471
Parham, C.L., C. Shaw, L.D. Auckland, S.K. Dickeson, I. Griswold-Prenner and G. Bix, Perlecan Domain V Inhibits Amyloid-b Induced Activation of the a2b1 Integrin-Mediated Neurotoxic Signaling Cascade (4) 1629–1647
Park, A., see Scharre, D.W. (3) 995–1004
Park, S.H., see Seo, E.H. (2) 559–568
Parkington, H.C., see Kuruppu, S. (3) 891–895
Parnetti, L., see Chiasserini, D. (1) 55–67
Pascale, A., see Marchesi, N. (2) 535–547
Pasinetti, G.M., see Varghese, M. (2) 477–496
Pasqualucci, C.A., see Grinberg, L.T. (1) 169–174
Pasquier, F., see Magnin, E. (4) 1459–1471
Passerini, G., see Mazzeo, S. (4) 1495–1508
Paterson, R.W., see Westona, P.S.J. (4) 1297–1302
Paxinos, G., see Fu, Y.H. (2) 569–584
Pedrós, I., see Ettcheto, M. (1) 233–251
Pelech, S.L., see Binukumar, B.K. (2) 525–533
Pellegrino, G., see Tombini, M. (4) 1619-1627
Pelleieux, S., see De Beaumont, L. (3) 913–922
Pendergrass, J.C., see Lozano, A.M. (2) 777–787
Pentzek, M., see Heser, K. (1) 185–199
Pentzek, M., see Wolfsgruber, S. (3) 1135–1146
Pepłońska, B., see Mandecka, M. (1) 157–168
Pereira, M.G., see Lima, S. (3) 1113–1121
Pérez-Grijalba, V., N. Fandos, J. Canudas, D. Insua, D. Casabona, A.M. Lacosta, M. Mon-tañés, P. Pesini and M. Sarasa, Validation of Immunoassay-Based Tools for the Comprehensive Quantification of A ι ι ι 40 and A ι ι ι 42 Peptides in Plasma (2) 751–762
Pesini, P., see Pérez-Grijalba, V. (2) 751–762
Peters, L., see Hülsemann, M. (1) 79–88
Peters, O., see Ritter, K. (4) 1319–1331
Petniak, A., see Ułamek-Kozioł, M. (1) 113–121
Petrella, R.J., see Heath, M. (3) 923–931
Petrov, D., see Ettcheto, M. (1) 233–251
Petukhova, E.O., see Mukhamedyarov, M.A. (4) 1373–1383
Piguet, O., see Midorikawa, A. (2) 549–558
Pinto, P., see Mazzeo, S. (4) 1495–1508
Pluta, J., see Gertje, E.C. (3) 1027–1037
Pluta, R., see Ułamek-Kozioł, M. (1) 113–121
Poirier, J., see De Beaumont, L. (3) 913–922
Polanco, J.C., see Baker, S. (3) 1207–1217
Ponce, F.A., see Lozano, A.M. (2) 777–787
Porsteinsson, A., see Ren, P. (1) 69–78
Porsteinsson, A.P., see Rosenberg, P.B. (1) 373–381
Portelius, E., E. Durieu, M. Bodin, M. Cam, J. Pannee, C. Leuxe, A. Mabondzo, N. Oumata, H. Galons, J.Y. Lee, Y.-T. Chang, K. Stüber, P. Koch, G. Fontaine, M.-C. Potier, A. Manousopoulou, S.D. Garbis, A. Covaci, D. Van Dam, P. De Deyn, F. Karg, M. Flajolet, C. Omori, S. Hata, T. Suzuki, K. Blennow, H. Zetterberg and L. Meijer, Specific Triazine Herbicides Induce Amyloid-b42 Production (4) 1593–1605
Posselt, T., see Heser, K. (1) 185–199
Potier, M.-C., see Portelius, E. (4) 1593–1605
Prasad, V., see Ritter, K. (4) 1319–1331
Qiu, T., X. Luo, Z. Shen, P. Huang, X. Xu, J. Zhou, M. Zhang and for the Alzheimer’s Disease Neuroimaging Initiative, Disrupted Brain Network in Progressive Mild Cognitive Impairment Measured by Eigenvector Centrality Mapping is Linked to Cognition and Cerebrospinal Fluid Biomarkers (4) 1483–1493
Quarmley, M., see Roalf, D.R. (1) 325–335
Racine, A.M., L.R. Clark, S.E. Berman, R.L. Koscik, K.D. Mueller, D. Norton, C.R. Nicholas, K. Blennow H. Zet-terbergj, B. Jedynak, M. Bilgel, C.M. Carlsson, B.T. Christian, S. Asthana and S.C. Johnson, Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Bi-omarkers in People at Risk for Alzheimer’s Disease (4) 1395–1408
Radko, S.P., see Khmeleva, S.A. (2) 809–819
Raffo, A., see Curiel, R.E. (2) 793–799
Rahimipour, S., see Tiiman, A. (3) 971–982
Rai, N., R. Kumar, G.R. Desai, G. Venugopalan, S. Shekhar, P. Chatterjee, M. Tripathi, A.D. Upadhyay, S. Dwivedi, A.B. Dey and S. Dey, Relative Alterations in Blood-Based Levels of Sestrin in Alzheimer’s Disease and Mild Cognitive Impairment Patients (3) 1147–1155
Rajapakse, N.W., see Kuruppu, S. (3) 891–895
Raman, R., see Rosenberg, P.B. (1) 373–381
Ramanan, S., see Bertoux, M. (3) 1005–1014
Ramirez, M.J., see Bengoetxea, X. (3) 1085–1094
Ransmayr, G., see Struhal, W. (2) 657–667
Ratti, A., see Marchesi, N. (2) 535–547
Rei, L., see Chincarini, A. (4) 1437–1457
Reis, H.J., see Mukhamedyarov, M.A. (4) 1373–1383
Reis, J., see Calderón-Garcidueñas, L. (2) 597–613
Ren, P., R.Y. Lo, B.P. Chapman, M. Mapstone, A. Porsteinsson, F. Lin and the Alzheimer’s Disease Neuroimaging Initiative, Longitudinal Alteration of Intrinsic Brain Activity in the Striatum in Mild Cognitive Impairment (1) 69–78
Renard, D., A. Gabelle, C. Hirtz, C. Demattei, E. Thouvenot and S. Lehmann, Cerebrospinal Fluid Alz-heimer’s Disease Biomarkers in Isolated Supratentorial Cortical Superficial Siderosis (4) 1291–1295
Reñé-Ramírez, R., see Turró-Garriga, O. (4) 1551–1560
Reyes, P., see Santamaría-García, H. (3) 957–970
Rezvanian, A., see Guo, L. (3) 1157–1167
Riedel-Heller, S.G., see Heser, K. (1) 185–199
Riedel-Heller, S.G., see Wolfsgruber, S. (3) 1135–1146
Riedeman, S.K., see Mueller, K.D. (4) 1539–1550
Rinne, J., see Iso-Markku, P. (4) 1303–1317
Ritter, K., C. Lange, M. Weygandt, A. Mäurer, A. Roberts, M. Estrella, P. Suppa, L. Spies, V. Prasad, I. Steffen, I. Apostolova, D. Bittner, M. Gövercin, W. Brenner, C. Mende, O. Peters, J. Seybold, J.B. Fiebach, E. Steinhagen-Thiessen, H. Hampel, J.-D. Haynes and R. Buchert, Combination of Structural MRI and FDG-PET of the Brain Improves Diagnostic Accuracy in Newly Manifested Cognitive Impairment in Geriatric Inpatients (4) 1319–1331
Rizvanov, A.A., see Mukhamedyarov, M.A. (4) 1373–1383
Roalf, D.R., M. Quarmley, D. Mechanic-Hamilton, D.A. Wolk, S.E. Arnold, P.J. Moberg and for the Alz-heimer’s Disease Neuroimaging Initiative, Within-Individual Variability: An Index for Subtle Change in Neurocognition in Mild Cognitive Impairment (1) 325–335
Robert, P., see Magnin, E. (4) 1459–1471
Roberts, A., see Ritter, K. (4) 1319–1331
Rogers, J., see McGeer, P.L. (3) 853–857
Roos, P., see Tiiman, A. (3) 971–982
Roose, D., see Blockx, I. (2) 723–735
Rosado, M., see Curiel, R.E. (2) 793–799
Roselli, F., see Li, Y. (1) 135–148
Rosenberg, P.B., K.L. Lanctôt, N. Herrmann, J.E. Mintzer, A.P. Porsteinsson, X. Sun and R. Raman, Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer’s Disease (1) 373–381
Rosenberg, P.B., see Lozano, A.M. (2) 777–787
Rossi, P.D., see Arosio, B. (2) 417–425
Rossor, M.N., see Westona, P.S.J. (4) 1297–1302
Ruiz-Ramos, R., see Calderón-Garcidueñas, L. (2) 597–613
Sabbagh, M., see Lozano, A.M. (2) 777–787
Sager, M.A., see Mueller, K.D. (4) 1539–1550
Salafutdinov, I.I., see Mukhamedyarov, M.A. (4) 1373–1383
Saling, M.M., see Malpas, C.B. (1) 223–232
Salloway, S., see Lozano, A.M. (2) 777–787
Salvadori, N., see Chiasserini, D. (1) 55–67
Samarasinghe, K., see Wijesinghe, P. (4) 1607–1618
Sandoval, K.E., see Farr, S.A. (4) 1339–1348
Santacruz, J.M., see Santamaría-García, H. (3) 957–970
Santa-Maria, I., see Varghese, M. (2) 477–496
Santamaría-García, H., P. Reyes, A. García, S. Baéz, A. Martinez, J.M. Santacruz, A. Slachevsky, M. Sigman, D. Matallana and A. Ibañez, First Symptoms and Neurocognitive Correlates of Behavioral Variant Frontotemporal Dementia (3) 957–970
Santangelo, R., see Mazzeo, S. (4) 1495–1508
Sao, T., see Yoshino, Y. (4) 1349–1357
Sarasa, M., see Pérez-Grijalba, V. (2) 751–762
Sarazin, M., see Bertoux, M. (3) 1005–1014
Sarkar, A., see Goldwaser, E.L. (2) 445–456
Scarpa, S., see Martire, S. (1) 307–324
Scarpini, E., see Cioffi, S.M.G. (2) 717–721
Scharre, D.W., S.-I. Chang, H.N. Nagaraja, A. Park, A. Adeli, P. Agrawal, A. Kloos, D. Kegelmeyer, S. Linder, N. Fritz, S.K. Kostyk and M. Kataki, Paired Studies Comparing Clinical Profiles of Lewy Body Dementia with Alzheimer’s and Parkinson’s Diseases (3) 995–1004
Scherbaum, N., see Klafki, H.-W. (2) 691–705
Scherer, M., see Heser, K. (1) 185–199
Scherer, M., see Wolfsgruber, S. (3) 1135–1146
Schlauch, K.A., see Mukhamedyarov, M.A. (4) 1373–1383
Schmidt, C., see Karch, A. (4) 1385–1393
Schmitz, M., see Karch, A. (4) 1385–1393
Schott, J.M., see Westona, P.S.J. (4) 1297–1302
Schuchhardt, J., see Klafki, H.-W. (2) 691–705
Scortichini, V., see Arosio, B. (2) 417–425
Selivanova, O.M., A.K. Surin, V.V. Marchenkov, U.F. Dzhus, E.I. Grigorashvili, M.Y. Suvorina, A.V. Glyakina, N.V. Dovidchenko and O.V. Galzitskaya, The Mechanism Underlying Amyloid Polymorphism is Opened for Alzheimer’s Disease Amy-loid- ι ι ι Peptide (2) 821–830
Sensi, F., see Chincarini, A. (4) 1437–1457
Seo, E.H., H. Kim, K.H. Lee and I.H. Choo, Altered Executive Function in Pre-Mild Cognitive Impairment (3) 933–940
Seo, E.H., S.H. Kim, S.H. Park, S.-H. Kang, I.H. Choo and for the Alzheimer’s Disease Neuroimaging Initiative, Topographical APOE ɛ4 Genotype Influence on Cerebral Metabolism in the Continuum of Alzheimer’s Disease: Amyloid Burden Adjusted Analysis (2) 559–568
Seo, S.W., see Noh, Y. (3) 1015–1026
Sepe-Monti, M., N. Vanacore, L. Bartorelli, A. Tognetti, F. Giubilei and Savvy Caregiver Study Group, The Savvy Caregiver Program: A Probe Multicenter Randomized Controlled Pilot Trial in Caregivers of Patients Affected by Alzheimer’s Disease (3) 1235–1246
Serpente, M., see Cioffi, S.M.G. (2) 717–721
Seybold, J., see Ritter, K. (4) 1319–1331
Shadman, A., see Brody, M. (4) 1509–1519
Shankar, S.K., see Wijesinghe, P. (4) 1607–1618
Shankle, W.R., J. Hara, L.W. Barrentine and M.V. Curole, CerefolinNAC Therapy of Hyperhomocysteinemia Delays Cortical and White Matter Atrophy in Alzheimer’s Disease and Cerebrovascular Disease (3) 1073–1084
Sharova, N.P., see Morozov, A.V. (2) 763–776
Shaw, C., see Parham, C.L. (4) 1629–1647
Shaw, L.M., see Durazzo, T.C. (1) 99–107
Shekhar, S., see Rai, N. (3) 1147–1155
Shen, D., see Zhang, H. (3) 1095–1112
Shen, Z., see Qiu, T. (4) 1483–1493
Shevchenko, G., see Musunuri, S. (4) 1671–1686
Shi, F., see Zhang, H. (3) 1095–1112
Shi, L., see Lou, W. (1) 397–409
ShiDu Yan, S., see Yu, Q. (2) 679–690
Shimada, H., see Makizako, H. (4) 1473–1482
Sholts, S.B., see Tiiman, A. (3) 971–982
Shu, H., see Chen, G. (3) 983–993
Shu, H., see Yuan, B. (4) 1409–1423
Shukla, V., see Binukumar, B.K. (2) 525–533
Sicari, M., see Tombini, M. (4) 1619–1627
Sigman, M., see Santamaría-García, H. (3) 957–970
Sinakos, Z., see Tsolaki, M. (1) 129–133
Singhrao S.K., see Olsen, I. (1) 45–53
Skuntz, S., see Binukumar, B.K. (2) 525–533
Slachevsky, A., see Bertoux, M. (3) 1005–1014
Slachevsky, A., see Santamaría-García, H. (3) 957–970
Smith, A.I., see Kuruppu, S. (3) 891–895
Smith, G.S., see Lozano, A.M. (2) 777–787
Smolek, T., see Zimova, I. (2) 831–843
Somers, C., H. Struyfs, J. Goossens, E. Niemantsverdriet, J. Luyckx, N. De Roeck, E. De Roeck, B. De Vil, P. Cras, J.-J. Martin, P.-P. De Deyn, M. Bjerke and S. Engelborghs, A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in Belgium (1) 383–395
Song, Y., see Li, Y. (1) 135–148
Soto, C., see Estrada, L.D. (3) 1193–1205
Spallazzi, M., see Cioffi, S.M.G. (2) 717–721
Spicer, A.J., see Kuruppu, S. (3) 891–895
Spies, L., see Ritter, K. (4) 1319–1331
Stavropoulos, T.G., see Lazarou, I. (4) 1561–1591
Stefani, M., see Luccarini, I. (2) 737–750
Steffen, I., see Ritter, K. (4) 1319–1331
Stein, J., see Heser, K. (1) 185–199
Stein, J., see Wolfsgruber, S. (3) 1135–1146
Steinbusch, H.W.M., see Wijesinghe, P. (4) 1607–1618
Steiner, J., see Binukumar, B.K. (2) 525–533
Steinhagen-Thiessen, E., see Ritter, K. (4) 1319–1331
Steinmann, S., see Wolfsgruber, S. (3) 1135–1146
Stevnsborg, L., C. Jensen-Dahm, T.R. Nielsen, C. Gasse and G. Waldemar, Inequalities in Access to Treatment and Care for Patients with Dementia and Immigrant Background: A Danish Nationwide Study (2) 505–514
Stevnsborg, L., see Zakarias, J.K. (3) 1183–1192
Steward, C., see Malpas, C.B. (1) 223–232
Stoops, E., see Chiasserini, D. (1) 55–67
Struhal, W., C. Mahringer, H. Lahrmann, C. Mörtl, P. Buhl, M. Huemer and G. Ransmayr, Heart Rate Spectra Confirm the Presence of Autonomic Dysfunction in Dementia Patients (2) 657–667
Struyfs, H., see Somers, C. (1) 383–395
Stüber, K., see Portelius, E. (4) 1593–1605
Styczyńska, M., see Mandecka, M. (1) 157–168
Su, J., see Li, D. (1) 89–98
Suh, Y.-H., see Kang, J.M. (3) 879–889
Suh, Y.-h., see Wijesinghe, P. (4) 1607–1618
Sun, H., see Sun, J. (1) 175–184
Sun, J., R. Cai, R. Huang, P. Wang, S. Tian, H. Sun, W. Xia and S. Wang, Cholesteryl Ester Transfer Protein Inti-mately Involved in Dyslipidemia-Related Susceptibility to Cognitive Deficits in Type 2 Diabetic Patients (1) 175–184
Sun, X., see Rosenberg, P.B. (1) 373–381
Suppa, P., see Ritter, K. (4) 1319–1331
Surin, A.K., see Selivanova, O.M. (2) 821–830
Sutter, C., see Binukumar, B.K. (2) 525–533
Suvorina, M.Y., see Selivanova, O.M. (2) 821–830
Suzuki, T., see Makizako, H. (4) 1473–1482
Suzuki, T., see Portelius, E. (4) 1593–1605
Swerdlow, R.H., see Yu, Q. (2) 679–690
Szekeres, P., see Mead, E. (4) 1521–1538
Tabira, T., see Hara, H. (3) 1047–1059
Taheri, S., J. Yu, H. Zhu and M.S. Kindy, High-Sodium Diet Has Opposing Effects on Mean Arterial Blood Pressure and Cerebral Perfusion in a Transgenic Mouse Model of Alzheimer’s Disease (3) 1061–1072
Takada, L.T., see Grinberg, L.T. (1) 169–174
Tales, A., see Jenkins, A. (3) 1169–1182
Tan, E.C.K., J.S. Bell, C.Y. Lu and S. Toh, National Trends in Outpatient Antihypertensive Prescribing in People with Dementia in the United States (4) 1425–1435
Tang-Wai, D.F., see Lozano, A.M. (2) 777–787
Targum, S.D., see Lozano, A.M. (2) 777–787
Taylor, J.-P., see Bonanni, L. (4) 1649–1657
Teixeira, A.L., see Mukhamedyarov, M.A. (4) 1373–1383
Teunissen, C.E., see van Steenoven, I. (1) 287–295
Thacker, E.L., see Cushman, M. (2) 497–503
Thomé, F., see Gomm, W. (2) 801–808
Thompson, C., see Calderón-Garcidueñas, L. (2) 597–613
Thornton, I.M., see Jenkins, A. (3) 1169–1182
Thouvenot, E., see Renard, D. (4) 1291–1295
Tian, S., see Sun, J. (1) 175–184
Tierney, M.C., see Jaakkimainen, R.L. (1) 337–349
Tiiman, A., J. Luo, C. Wallin, L. Olsson, J. Lindgren, J. Jarvet, P. Roos, S.B. Sholts, S. Rahimipour, J.P. Abrahams, A.E. Karlström, A. Gräslund and S.K.T.S. Wärmländer, Specific Binding of Cu(II) Ions to Amyloid-Beta Peptides Bound to Aggregation-Inhibiting Molecules or SDS Micelles Creates Complexes that Generate Radical Oxygen Species (3) 971–982
Tio, G., see Magnin, E. (4) 1459–1471
Tognetti, A., see Sepe-Monti, M. (3) 1235–1246
Toh, S., see Tan, E.C.K. (4) 1425–1435
Tombini, M., M. Sicari, G. Pellegrino, F. Ursini, P. Insardá and V. Di Lazzaro, Nutritional Status of Patients with Alzheimer’s Disease and Their Caregivers (4) 1619–1627
Torres-Jardón, R., see Calderón-Garcidueñas, L. (2) 597–613
Trebbastoni, A., F. D’Antonio, C. de Lena, E. Onesti, B. John and M. Inghilleri, Primary Progressive Orofacial Apraxia: A Ten-Year Long Follow-Up Case Report (3) 1039–1045
Tripathi, M., see Rai, N. (3) 1147–1155
Troakes, C., see Mirzaa, A. (4) 1333–1338
Trojanowski, J.Q., see Durazzo, T.C. (1) 99–107
Troussière, A.-C., see Magnin, E. (4) 1459–1471
Trumbore, C.N., Shear-Induced Amyloid Formation in the Brain: I. Potential Vascular and Parenc hymal Processes (2) 457–470
Tsolaki, A., see Tsolaki, M. (1) 129–133
Tsolaki, M., E. Karathanasi, I. Lazarou, K. Dovas, E. Verykouki, A. Karakostas, K. Georgiadis, A. Tsolaki, K. Adam, I. Kompatsiaris and Z. Sinakos, Efficacy and Safety of Crocus sativus L. in Patients with Mild Cognitive Impairment: One Year Single-Blind Randomized, with Parallel Groups, Clinical Trial (1) 129–133
Tsolaki, M., see Lazarou, I. (4) 1561–1591
Tsompanidis, T., see Lazarou, I. (4) 1561–1591
Tsoy, E., see Levy, B. (4) 1259–1272
Tsutsumimoto, K., see Makizako, H. (4) 1473–1482
Tu, K., see Jaakkimainen, R.L. (1) 337–349
Turkstra, L.S., see Mueller, K.D. (4) 1539–1550
Turró-Garriga, O., J. Garre-Olmo, R. Reñé-Ramírez, L. Calvó-Perxas, J. Gascón-Bayarri and J.-L. Conde-Sala, Consequences of Anosognosia on the Cost of Caregivers’ Care in Alzheimer’s Disease (4) 1551–1560
Ueno, S.-i., see Yoshino, Y. (4) 1349–1357
Ułamek-Kozioł, M., J. Kocki, A. Bogucka-Kocka, A. Petniak, P. Gil-Kulik, S. Januszewski, J. Bogucki, M. Jabłoński, W. Furmaga-Jabłońska, J. Brzozowska, S.J. Czuczwar and R. Pluta, Dysregulation of Autophagy, Mitophagy, and Apoptotic Genes in the Medial Temporal Lobe Cortex in an Ischemic Model of Alzheimer’s Disease (1) 113–121
Unverzagt, F.W., see Cushman, M. (2) 497–503
Upadhyay, A.D., see Rai, N. (3) 1147–1155
Ursini, F., see Tombini, M. (4) 1619–1627
Valachova, B., see Zimova, I. (2) 831–843
Van Dam, D., see Portelius, E. (4) 1593–1605
van der Flier, W.M., see van Steenoven, I. (1) 287–295
Van der Linden, A., see Blockx, I. (2) 723–735
van Steenoven, I., D. Aarsland, D. Weintraub, E. Londos, F. Blanc, W.M. van der Flier, C.E. Teunissen, B. Mollenhauer, T. Fladby, M.G. Kramberger, L. Bonanni, A.W. Lemstra and on behalf of the EuropeanDLB consortium, Cerebrospinal Fluid Alzheimer’s Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort (1) 287–295
Vanacore, N., see Sepe-Monti, M. (3) 1235–1246
Vanderstichele, H., see Chiasserini, D. (1) 55–67
Varghese, M., I. Santa-Maria, L. Ho, L. Ward, S. Yemul, L. Dubner, H. Ksie?z?ak-Reding and G.M. Pasinetti, Extracellular Tau Paired Helical Filaments Differentially Affect Tau Pathogenic Mechanisms in Mitotic and Post-Mitotic Cells: Implications for Mechanisms of Tau Propagation in the Brain (2) 477–496
Velakoulis, D., see Malpas, C.B. (1) 223–232
Venugopalan, G., see Rai, N. (3) 1147–1155
Verhoye, M., see Blockx, I. (2) 723–735
Verykouki, E., see Tsolaki, M. (1) 129–133
Vieira, L.B., see Mukhamedyarov, M.A. (4) 1373–1383
Vijayan, M. and P. Hemachandra Reddy, Stroke, Vascular Dementia, and Alzheimer’s Disease: Molecular Links (2) 427–443
Villalobos, C., see Calvo-Rodríguez, M. (1) 207–221
Villarreal, A.E., S. Grajales, S.E. O’Bryant, M. Edwards, L. López, A. Montalván and G.B. Britton for the Panama Aging Research Initiative (PARI), Characterization of Alzheimer’s Disease and Mild Cognitive Impairment in Older Adults in Panama (3) 897–901
Vintimilla, R., see Johnson, L.A. (1) 201–206
Vivash, L., see Malpas, C.B. (1) 223–232
Volpe-Gillot, L., see Magnin, E. (4) 1459–1471
von Bernhardi, R., see Estrada, L.D. (3) 1193–1205
von Holt, K., see Gomm, W. (2) 801–808
Vuoksimaa, E., see Iso-Markku, P. (4) 1303–1317
Wadley, V.G., see Cushman, M. (2) 497–503
Wagner, M., see Heser, K. (1) 185–199
Wagner, M., see Wolfsgruber, S. (3) 1135–1146
Waldemar, G., see Stevnsborg, L. (2) 505–514
Waldemar, G., see Zakarias, J.K. (3) 1183–1192
Waldorff, F.B., see Zakarias, J.K. (3) 1183–1192
Waller, K., see Iso-Markku, P. (4) 1303–1317
Wallin, C., see Tiiman, A. (3) 971–982
Wallon, D., see Magnin, E. (4) 1459–1471
Wandosell, F., see Ordoñez-Gutierrez, L. (2) 645–656
Wang, D., see Lou, W. (1) 397–409
Wang, H., Y. Wang, X. Hong, S. Li and Y. Wang, Quantitative Proteomics Reveals the Mechanism of Oxygen Treatment on Lenses of Alzheimer’s Disease Model Mice (1) 275–286
Wang, P., K. Chen, L. Yao, B. Hu, X. Wu, J. Zhang, Q. Ye and X. Guo, for the Alzheimer’s Disease Neu-roimaging Initiative, Multimodal Classification of Mild Cognitive Impairment Based on Partial Least Squares (1) 359–371
Wang, P., see Sun, J. (1) 175–184
Wang, S., see Sun, J. (1) 175–184
Wang, W., see Yu, L. (1) 297–306
Wang, Y., see Wang, H. (1) 275–286
Wang, Y., see Wang, H. (1) 275–286
Wang, Z., see Yuan, B. (4) 1409–1423
Ward, B.D., see Chen, G. (3) 983–993
Ward, J., see Connors, M.H. (1) 149–155
Ward, L., see Varghese, M. (2) 477–496
Wärmländer, S.K.T.S., see Tiiman, A. (3) 971–982
Warren, J.D., see Westona, P.S.J. (4) 1297–1302
Weckbecker, K., see Gomm, W. (2) 801–808
Weeg, D., see Heser, K. (1) 185–199
Weiler, J., see Heath, M. (3) 923–931
Weiner, M.W., see Durazzo, T.C. (1) 99–107
Weiner, M.W., see Noh, Y. (3) 1015–1026
Weintraub, D., see van Steenoven, I. (1) 287–295
Weiser, B., see Johnson, L.A. (1) 201–206
Weisova, P., see Zimova, I. (2) 831–843
Werle, J., see Heser, K. (1) 185–199
Werle, J., see Wolfsgruber, S. (3) 1135–1146
Werth, J.L., see Brody, M. (4) 1509–1519
Westona, P.S.J., R.W. Paterson, J. Dickson, A. Barnes, J.B. Bomanji, I. Kayani, M.P. Lunn, C.J. Mummery, J.D. Warren, M.N. Rossor, N.C. Fox, H. Zetterberg and J.M. Schott, Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid? (4) 1297–1302
Wetterhall, M., see Musunuri, S. (4) 1671–1686
Weyerer, S., see Heser, K. (1) 185–199
Weyerer, S., see Wolfsgruber, S. (3) 1135–1146
Weygandt, M., see Ritter, K. (4) 1319–1331
Widdifield, J., see Jaakkimainen, R.L. (1) 337–349
Wiese, B., see Heser, K. (1) 185–199
Wiese, B., see Wolfsgruber, S. (3) 1135–1146
Wijesinghe, P., S.K. Shankar, T.C. Yasha, C. Gorrie, D. Amaratunga, S. Hulathduwa, K.S. Kumara, K. Samara-singhe, Y.-h. Suh, H.W.M. Steinbusch and K.R.D. De Silva, Vascular Contributions in Alzheimer’s Disease-Related Neuropathological Changes: First Autopsy Evidence from a South Asian Aging Population (4) 1607–1618
Willbold, D., see Hülsemann, M. (1) 79–88
Willbold, J., see Hülsemann, M. (1) 79–88
Willbold, S., see Hülsemann, M. (1) 79–88
Willich, S.N., see Brüuggenjürgen, B. (4) 1365–1372
Wiltfang, J., see Klafki, H.-W. (2) 691–705
Witt, K.A., see Farr, S.A. (4) 1339–1348
Wolak, J., see Mead, E. (4) 1521–1538
Wolfsgruber, S., L. Kleineidam, M. Wagner, E. Mösch, H. Bickel, D. Lühmann, A. Ernst, B. Wiese, S. Steinmann, H.-H. König, C. Brettschneider, T. Luck, J. Stein, S. Weyerer, J. Werle, M. Pentzek, A. Fuchs, W. Maier, M. Scherer, S.G. Riedel-Heller, F. Jessen and for the AgeCoDe Study Group, Differential Risk of Incident Alzheimer’s Disease Dementia in Stable Versus Unstable Patterns of Subjective Cognitive Decline (3) 1135–1146
Wolk, D., see Gertje, E.C. (3) 1027–1037
Wolk, D.A., see Lozano, A.M. (2) 777–787
Wolk, D.A., see Roalf, D.R. (1) 325–335
Wong, A., see Lou, W. (1) 397–409
Wong, S., see Bertoux, M. (3) 1005–1014
Wong, T.Y., see Liu, S. (2) 585–595
Woodward, M., see Connors, M.H. (1) 149–155
Wu, X., see Wang, P. (1) 359–371
Wu, Y., see Li, Y. (1) 135–148
Xia, W., see Sun, J. (1) 175–184
Xiao, Z., see Yu, L. (1) 297–306
Xie, C., see Yuan, B. (4) 1409–1423
Xu, X., see Qiu, T. (4) 1483–1493
Yadav, M., see Johnson, L.A. (1) 201–206
Yakupov, E.Z., see Mukhamedyarov, M.A. (4) 1373–1383
Yamazaki, K., see Yoshino, Y. (4) 1349–1357
Yañez, M.J., see Estrada, L.D. (3) 1193–1205
Yang, Y.-H., see Ho, B.-L. (1) 351–357
Yao, L., see Wang, P. (1) 359–371
Yasha, T.C., see Wijesinghe, P. (4) 1607–1618
Ye, B.S., see Noh, Y. (3) 1015–1026
Ye, Q., see Wang, P. (1) 359–371
Yemul, S., see Varghese, M. (2) 477–496
Yeon, B.K., see Kang, J.M. (3) 879–889
Yoon, C.W., see Noh, Y. (3) 1015–1026
Yoshida, T., see Yoshino, Y. (4) 1349–1357
Yoshino, Y., T. Mori, T. Yoshida, K. Yamazaki, Y. Ozaki, T. Sao, Y. Funahashi, J.-i. Iga and S.-i. Ueno, Elevated mRNA Expression and Low Methylation of SNCA in Japanese Alzheimer’s Disease Subjects (4) 1349–1357
Young, J., see Jaakkimainen, R.L. (1) 337–349
Yu, H., see Yu, Q. (2) 679–690
Yu, J., see Taheri, S. (3) 1061–1072
Yu, L., Y. Chen, W. Wang, Z. Xiao and Y. Hong, Multi-Vitamin B Supplementation Reverses Hypoxia-Induced Tau Hyperphosphorylation and Improves Memory Function in Adult Mice (1) 297–306
Yu, Q., D. Fang, R.H. Swerdlow, H. Yu, J.X. Chen and S. ShiDu Yan, Antioxidants Rescue Mitochondrial Transport in Differentiated Alzheimer’s Disease Trans-Mitochondrial Cybrid Cells (2) 679–690
Yuan, B., C. Xie, H. Shu, W. Liao, Z. Wang, D. Liu and Z. Zhang, Differential Effects of APOE Genotypes on the Anterior and Posterior Subnetworks of Default Mode Network in Amnestic Mild Cognitive Impairment (4) 1409–1423
Yushkevich, P., see Gertje, E.C. (3) 1027–1037
Zafar, S., see Karch, A. (4) 1385–1393
Zafiu, C., see Hülsemann, M. (1) 79–88
Zago, W., see Blockx, I. (2) 723–735
Zakarias, J.K., C. Jensen-Dahm, A. Nørgaard, L. Stevnsborg, C. Gasse, B.G. Andersen, S. Jakobsen, F.B. Waldorff, T. Moos and G. Waldemar, Geographical Variation in Antipsychotic Drug Use in Elderly Patients with Dementia: A Nationwide Study (3) 1183–1192
Zanlungo, S., see Estrada, L.D. (3) 1193–1205
Zefirov, A.L., see Mukhamedyarov, M.A. (4) 1373–1383
Zerr, I., see Karch, A. (4) 1385–1393
Zetterberg, H., see Portelius, E. (4) 1593–1605
Zetterberg, H., see Racine, A.M. (4) 1395–1408
Zetterberg, H., see Westona, P.S.J. (4) 1297–1302
Zhang, H., X. Chen, F. Shi, G. Li, M. Kim, P. Giannakopoulos, S. Haller and D. Shen, Topographical Infor-mation-Based High-Order Functional Connectivity and Its Application in Abnormality Detection for Mild Cognitive Impairment (3) 1095–1112
Zhang, J., see Wang, P. (1) 359–371
Zhang, M., see Qiu, T. (4) 1483–1493
Zhang, Y.-X., see Li, D. (1) 89–98
Zhang, Z., see Chen, G. (3) 983–993
Zhang, Z., see Yuan, B. (4) 1409–1423
Zhou, J., see Liu, S. (2) 585–595
Zhou, J., see Qiu, T. (4) 1483–1493
Zhou, W., see Li, Y. (1) 135–148
Zhou, W.-X., see Li, D. (1) 89–98
Zhou, X., see Beckelman, B.C. (2) 669–678
Zhu, H., see Taheri, S. (3) 1061–1072
Zilka, N., see Zimova, I. (2) 831–843
Zimova, I., V. Brezovakova, T. Hromadka, P. Weisova, V. Cubinkova, B. Valachova, P. Filipcik, S. Jadhav, T. Smolek, M. Novak and N. Zilka, Human Truncated Tau Induces Mature Neurofibrillary Pathology in a Mouse Model of Human Tauopathy (2) 831–843
